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ABSTRACT
Alzheimer’s disease (AD), the most common form of dementia, is characterized by 
extracellular plaques in the brain created when monomeric amyloid-β (Aβ) protein 
aggregates into fibrillar structures.  Soluble Aβ aggregates, including oligomers, that form 
along the reaction pathway are believed to be the primary pathogenic species and have 
been shown to increase the production of reactive oxygen species (ROS).  This 
upregulation of ROS is one suggested contributing factor of Aβ aggregate cytotoxicity and 
has proven capable of mediating cell signaling associated with Aβ aggregate-induced 
cellular responses.   
Polyphenols have been suggested as a complimentary AD therapeutic based on 
epidemiological evidence that polyphenol-rich diets correlate with a reduced incidence of 
AD.  Polyphenols have demonstrated the ability to inhibit Aβ aggregation thereby 
neutralizing the protein’s damaging effects.  Additionally, polyphenols may counteract Aβ 
aggregate-induced cellular responses by neutralizing ROS through their antioxidant 
properties.  This study sought to identify polyphenols that can reduce Aβ oligomer-induced 
cellular responses by 1) altering oligomer formation via changing oligomer size 
distribution and/or modulating oligomer conformation and 2) exerting antioxidant 
capabilities.  The ability of polyphenols to function as dual-action therapeutics for AD by 
acting through both mechanisms was also explored. 
 Many of the studied polyphenols exhibited the ability to alter oligomer formation 
by both reducing the amount of 25 – 250 kDa oligomers formed and by changing oligomer 
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surface hydrophobicity.  Key polyphenol structural elements were identified that dictate 
the polyphenol’s ability to alter oligomer formation, providing insights into the optimum 
inhibitor structure.  Additionally, these polyphenol-induced changes in A oligomer size 
distribution and structure resulted in lowered cellular responses, including both 
intracellular ROS and caspase activation.  Polyphenols also exhibited strong antioxidant 
capabilities, and thus many polyphenols were able to reduce intracellular ROS and caspase 
activation induced by native A oligomers.  These findings demonstrate that polyphenols 
can attenuate oligomer-induced cellular responses even without altering oligomer 
formation.  Studies also investigated by which mechanism each polyphenol primarily 
reduces oligomer-induced cellular responses and identified the polyphenol kaempferol as 
a potential dual-action therapeutic exhibiting synergy between the two mechanisms.  
Combined, these studies identify several promising polyphenols for use as natural 
therapeutics for AD.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE 
1.1 Alzheimer’s Disease and the Role of the Amyloid-β Protein  
Alzheimer’s disease (AD) is the most common neurodegenerative disease and 
affects an estimated 5.3 million people in the United States alone.1  This number is expected 
to increase as the population of people over the age of 65 continues to grow.  While other 
top leading causes of death such as heart disease, stroke, and HIV have decreased between 
the years 2000 and 2010, the number of fatalities due to AD has increased 68%.2  Despite 
the overwhelming need for treatment, there is currently no way to stop or even slow the 
progression of AD.1  Drugs that are FDA approved, such as Namenda and Razadyne, only 
treat the symptoms associated with AD and become increasingly ineffective as the disease 
continues to progress.3  Common effects of AD include disorientation, loss of long-term 
memory, deteriorating motor function and communication skills, and abrupt changes in 
behavior.1,4–6 
The hallmarks of this disease, pathological neurofibrillary tangles and extracellular 
plaques, were first observed in 1907 by Alois Alzheimer.7  The neurofibrillary tangles are 
composed of filamentous deposits of the tau protein while the extracellular plaques are 
fibrillary deposits of the amyloid-β protein (Aβ).  Since Aβ is not found in other 
neurodegenerative disorders associated with tau such as Pick’s disease, progressive 
supranuclear palsy, and corticobasal degeneration, tau dysfunction is not believed to lead 
to amyloid plaques.8,9  When mice exhibiting both amyloid plaque and tau neurofibrillary 
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tangle pathology were immunized against Aβ, levels of tau were also reduced.10  
Additionally, studies have demonstrated that Aβ deposits appear first in AD mouse 
models,11 further implicating that, although neurofibrillary tangles can induce severe 
neurodegeneration, it is the accumulation of Aβ predominantly responsible for AD 
pathogenesis, making it a primary target for AD therapeutics.11–13 
Aβ is cleaved from the amyloid precursor protein (APP)14–17  While its function is 
still unknown, Aβ occurs naturally in blood, plasma, and cerebrospinal fluid and is not 
harmful in it monomeric form.  In the case of AD, the monomeric form of Aβ 
self-assembles into insoluble extracellular plaques characteristic of the disease.  The two 
main isoforms of Aβ contain 40 (Aβ1-40) or 42 (Aβ1-42) residues.18,19  Aβ1-40 is the more 
abundant isoform but is primarily found in vascular amyloid deposits, while Aβ1-42, the 
more hydrophobic of the two isoforms, deposits first in the brain and is more prone to 
aggregation and fibril formation.16,17  While the Aβ aggregation pathway has proved very 
complex and is still not completely understood, the basic Aβ aggregation pathway is known 
to consist of lag, growth, and plateau phases (Figure 1.1).  The aggregation begins when 
Aβ undergoes nucleation, which is the rate limiting step of the aggregation process (lag 
phase).9,16  Next, soluble Aβ aggregates (which initiate as oligomers) continue to grow via 
lateral association and elongation by monomer addition until mature insoluble fibrils are 
formed, which deposit as plaques in the brain.  Intervening in the aggregation pathway to 
either stop or slow the formation of aggregates has long been of interest as a therapeutic 
strategy.  
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1.2 The Damaging Effects of Aβ Oligomers 
Originally, large insoluble fibrils were believed to be the causative agent in AD 
progression; however, mounting evidence now supports that it is the smaller soluble 
oligomers that are primarily responsible.  Neurological deficits associated with AD occur 
in the absence of fibrils in transgenic mouse models,20 and the neurotoxic effect is 
independent of Aβ plaque formation.21,22  In contrast, the presence of Aβ oligomers has 
been shown to cause neurodegeneration and correlates strongly with AD associated 
dementia.23–25  Specifically, Aβ oligomers can induce neurotoxcity,26 synapse loss,27–29 and 
impaired memory.30  Our lab has previously demonstrated that small soluble Aβ aggregates 
increase inflammatory responses, such as endothelial monolayer permeability, monocyte 
adhesion, and monocyte transmigration, while monomeric Aβ and mature Aβ fibrils are 
inert.31,32   
Oxidative stress has also been implicated as a contributing factor to the cytotoxicity 
of Aβ.33  Aβ has been shown to induce intracellular reactive oxygen species (ROS) which 
have proven capable of mediating cell signaling associated with Aβ-induced cellular 
responses.34–36  Furthermore, ROS is known to cause mitochondrial damage which can lead 
to caspase activation.37  Caspases regulate vital cell networks responsible for inflammation 
and apoptosis.38  Since Aβ aggregates are foreign molecular structures, just their presence 
can trigger these inflammatory and apoptotic responses.39  Studies have shown that Aβ 
oligomers can activate NLRP3 inflammasome, a caspase promotor, and disrupt potassium 
channels leading to caspase-regulated inflammatory responses.39  Additionally, AD 
patient’s brain and plasma as well as transgenic AD mice show significant upregulation of 
caspase activation39  Once activated, caspases have been shown to further the pathology of 
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AD by inducing tau cleavage, promoting tau tangle formulation, and cleaving APP.39  Both 
ROS and caspase activation can be upregulated by Aβ oligomers and have been studied for 
their role in AD, thus making the reduction of these cellular responses a key therapeutic 
strategy for AD. 
1.3 Alteration of Aβ Oligomers by Polyphenols as a Therapeutic Approach for AD 
Studies have demonstrated that both oligomer size and conformation effect 
oligomer induced cellular responses.40–42  For example, lower molecular weight oligomers 
induce memory impairment associated with hippocampal synaptophysin while higher 
molecular weight oligomers induce greater oxidative stress.40  Additionally, Aβ oligomers 
of similar size but with different surface hydrophobicities41 or conformations43 elicit 
different toxic cellular responses. Therefore, compounds that are able to alter both A 
oligomer size distribution and conformation could reduce Aβ-induced cellular toxicity.   
Small molecules as inhibitors for Aβ aggregation have been a focus since early 
studies showed that Congo red and thioflavin T, both small aromatic molecules, interact 
specifically with Aβ fibrils and are capable of inhibiting fibril formation.44–46  Polyphenols, 
compounds found in fruits, vegetables, and herbs, have attracted interest because of their 
aromatic structure and ability to serve as a natural therapeutic.  Epidemiological studies 
have shown that diets rich in polyphenols result in a reduced incidence of AD.47–49  
Additionally, the aromatic carbon ring present in polyphenols has been shown to bind to 
Aβ oligomers thereby preventing further aggregation.50,51  Many polyphenols have 
demonstrated the ability to obstruct the Aβ aggregation pathway, including quercetin,52 
resveratrol,53 myricetin,52 curcumin,54 and piceid.55  Polyphenols also bind to many proteins 
altering the protein aggregate conformation.56  MegaNatural-AZ, a polyphenol derived 
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from grape seed, and oleocanthal, a phenolic compound found in olive oil, both effect Aβ-
induced cellular toxicity by altering Aβ aggregate conformation.57,58  Combined, these 
studies suggest that polyphenols have the potential to reduce Aβ-induced cellular responses 
by altering Aβ oligomer formation.  
1.4 Polyphenols’ Antioxidant Capabilities as a Therapeutic Approach for AD 
Antioxidants have been studied as treatments for oxidative-stress-induced cellular 
apoptosis observed in several neurodegenerative diseases including AD, Parkinson’s 
disease, and stroke.33  It has further been demonstrated that antioxidants, which neutralize 
ROS, have the ability to inhibit Aβ cytotoxicity.59,60  Polyphenols serve as the most 
abundant antioxidants in diet61 and their antioxidant capabilities are believed to play a role 
in their ability to effect various diseases.62–64  Many polyphenols have demonstrated the 
ability to neutralize the increased ROS induced by Aβ aggregates.44,47,65–67  This 
observation suggests that polyphenols could act as effective inhibitors of Aβ-induced 
cellular responses by attenuating increased ROS, giving polyphenols the potential to act as 
dual action therapeutics for AD by both altering Aβ oligomer formation and reducing ROS.  
1.5 Study Overview  
This study investigated the hypothesis that polyphenols can act as dual action 
therapeutics for AD by acting through two separate mechanisms: 1) by altering Aβ 
oligomer formation and 2) by reducing ROS through antioxidant capabilities.  Before dual 
action capabilities could be assessed, polyphenols’ ability to act through each mechanism 
was investigated separately.  These studies as well as the dual action study make up the 
three primary aims of this work and are described below.  
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1.5.1 Polyphenols attenuate Aβ-induced cellular responses by altering oligomer size and 
conformation  
This aim tests the hypothesis that polyphenols present during Aβ oligomer 
formation will alter the resulting oligomers by either changing the oligomer size 
distribution and/or altering oligomer conformation.  Furthermore, this aim determines if 
these oligomer alterations attenuate Aβ-induced cellular responses.  The size distribution 
of oligomers formed in the absence or presence of polyphenols was analyzed using 
SDS-PAGE and Western blot while the resulting oligomer conformation was examined 
using either ANS or Nile Red spectroscopy.  The effect these changes have on Aβ-induced 
cellular responses was evaluated by comparing intracellular ROS and caspase activity in 
neuroblastoma cells treated with Aβ oligomers formed in the absence or presence of 
selected polyphenols.   
1.5.2 Polyphenols attenuate Aβ-induced cellular responses by reducing intracellular ROS 
through their antioxidant capabilities  
This aim tests the hypothesis that polyphenols’ antioxidant capabilities can 
attenuate Aβ-induced intracellular ROS and that this reduction in ROS also decreases 
caspase activation.  Polyphenols with high antioxidant capability were identified through 
an oxygen radical absorbance capacity (ORAC) assay.  As in Aim 1, an intracellular ROS 
assay was employed, this time to ensure that the high antioxidant capabilities translated 
into a reduction of intracellular ROS induced by Aβ oligomers.  Additionally, the effect 
that the reduction of ROS had on Aβ oligomer induced caspase activation was investigated 
by comparing the caspase activity in cells treated with Aβ oligomers alone to cells treated 
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simultaneously with Aβ oligomers and polyphenols at a concentration shown to reduce 
intracellular ROS.  
1.5.3 Polyphenols can act as dual action therapeutics for AD by both altering Aβ 
oligomer formation and by reducing intracellular ROS. 
This aim tests the hypothesis that polyphenols that exhibit both mechanisms of 
inhibition, alteration to Aβ oligomer formation and neutralization of intracellular ROS, can 
act as dual action inhibitors against Aβ-induced cellular responses.  To explore the potential 
of dual action between the two mechanisms, cells were treated with oligomers formed in 
the presence of polyphenols along with enough additional polyphenol to allow for ROS 
inhibition. Polyphenols that reduced intracellular ROS and/or caspase activation by a 
greater amount than the reduction seen in the first and second aims were identified as dual 
action therapeutics for AD.  
These three hypotheses were tested using two separate sets of polyphenols.  The 
first set, discussed in Chapter 3, was selected in order to evaluate the effect that hydroxyl 
placement on the polyphenol ring structure has on inhibitory capability. The second set, 
discussed in Chapter 4, investigates the changes in inhibitory capability when a polyphenol 
is metabolized resulting in the replacement of a hydroxyl group with a methoxy group on 
the polyphenol ring. 
1.6 Innovation 
While epidemiological studies support the ability of polyphenols to attenuate 
AD,47–49 further studies are needed to elucidate the mechanism by which polyphenols 
intervene in the disease process.  This research investigates two mechanisms by which 
polyphenols can inhibit the cellular responses caused by Aβ.  The first mechanism, altering 
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oligomer formation, has not been fully explored, with most studies focusing on 
polyphenols’ ability to inhibit the formation of fibrils, the last stage of the aggregation 
process.52,53,55,68–70  More data is needed on the ability of polyphenols to inhibit the early 
stages of aggregation, specifically oligomer formation, which is thought to be the Aβ 
species primarily responsible for pathogenisis.23,24  This study also aids in determining if 
inhibition of fibril formation coincides with inhibition of oligomerization or if these 
inhibitory effects are achieved by independent mechanisms.  Additionally, this study gains 
insight into which polyphenol subclass and functionalization is most effective at 
modulating oligomerization by exploring an array of polyphenol structures.    
Reduction of Aβ-induced intracellular ROS through antioxidant capabilities is the 
second mechanism that is explored.  Various studies have evaluated the antioxidant 
capabilities of extracts from foods rich in polyphenols;71–73 however, this study determines 
the antioxidant capabilities of isolated polyphenols and the effect these capabilities have 
on Aβ-induced intracellular ROS.  This study also investigated the importance of 
Aβ-mediated ROS second messengers to caspase activity and the ability of polyphenols to 
counteract this process. 
While polyphenols have been studied previously for both of the described 
inhibitory mechanisms, which mechanism is most effective at reducing Aβ-induced 
cellular responses is unknown.  This study gains insight into the predominant inhibitory 
mechanism as well as determines the ability of these two mechanisms to work together to 
reduce Aβ induced cellular responses.  The combined results of this study will direct future 
work in identifying the best natural therapeutics for AD and will identify effective 
polyphenols to use as lead compounds for therapeutic development.  
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Figure 1.1 The progression of Aβ aggregation. Aβ monomer undergoes a 
rate-limiting nucleation lag phase followed by growth of soluble aggregates. 
These aggregates can then elongate or associate to form insoluble fibrils. 
Finally a plateau is reached where fibrils, soluble aggregates, and monomers 
are in equilibrium. Double arrows indicate equilibrium reactions.  
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CHAPTER 2
MATERIALS AND METHODS 
2.1 Materials  
Aβ1-42 was purchased from AnaSpec, Inc. (San Jose, CA), and the OxiSelect™ 
Oxygen Radical Antioxidant Capacity (ORAC) activity assay was purchased from Cell 
Biolabs (San Diego, CA).  Lamilli buffer, Tricene sample buffer, 4-20% tris-glycine gels, 
16.5% tris-tricine gels, Precision Plus Protein WesternC standard, Precision Plus Protein 
Dual Xtra standard, and 0.2 µm nitrocellulose membrane were purchased from Bio-Rad 
(Hercules, CA).  Monoclonal antibody 6E10 was obtained from Covance (Princeton, NJ). 
1, 1, 1, 3, 3, 3-hexafluoro-2-propanol (HFIP) was purchased from Sigma Aldrich 
(St. Louis, MO).  8-anilino-1-naphthalenesulphonic acid (ANS) was obtained from 
Research Organics (Cleveland, OH). HRP-conjugated anti-mouse secondary antibody, 
dimethyl sulfoxide (DMSO), Tween-20 and chemiluminescent reagents were purchased 
from VWR (Radnor, PA).  Nile Red, the Image-iT LIVE Green poly-caspase kit, and 
2’, 7’ dichlorodihydrofluoescein diacetate (DCFH-DA) were purchased from Life 
Technologies (Carlsbad, CA).  
2.2 Preparation of Aβ1-42 Oligomers 
Aβ1-42 was reconstituted in cold HFIP to 4 mg/mL and incubated on ice for 60 min.  
The protein solution was aliquoted, and the HFIP was allowed to evaporate overnight at 
25 °C.  Resulting protein films were stored at -80 °C until use.  To form Aβ1-42 oligomers, 
protein films were reconstituted in DMSO to 1.5 mM and combined with 10-fold molar 
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excess polyphenol (prepared fresh at 10mM in DMSO) or an equivalent volume of DMSO 
(control).  To initiate oligomerization, 12 mM phosphate buffer (pH 7.4) containing 1 µM 
NaCl was added to the sample for a final concentration of 15 µM Aβ1-42, 150 µM 
polyphenol, and ≤ 2.5% DMSO.  Following 30 min incubation (25 °C), reactions were 
stabilized by the addition of Tween-20 (final concentration of 0.1%) for SDS-PAGE and 
Western blot analysis or were immediately diluted for ANS spectroscopy, Nile Red 
spectroscopy, or cell culture assays.  
2.3 Determination of Aβ1-42 Oligomer Size via SDS-PAGE and Western Blot 
To determine whether polyphenols present during oligomerization alter oligomer 
size distribution, Tween-20 stabilized oligomers formed in the absence (control) or 
presence of polyphenols were mixed 1:1 with Lamilli buffer for size characterization using 
SDS-PAGE and Western blot.  For quantification of oligomers 25-250 kDa in size, samples 
were loaded onto a 4-20% Tris-glycine gel and electrophoresed (120 V) using a 
Mini-PROTEAN Tetra Cell (Bio-rad). Precision Plus Protein WesternC standard was used 
for size determination.  Protein was electrotransferred (14 V, 12 min) onto 0.2 µm 
nitrocellulose membrane (Bio-Rad) using a Trans-blot SD semi-dry transfer cell 
(Bio-Rad).  For quantification of monomer, trimer, and tetramer bands, stabilized 
oligomers were instead mixed 1:2 with Tricene sample buffer, loaded onto a 16.5% 
Tris-tricine gel, electrophoresed (100V), and electrotransferred (13 V, 12 min) onto 0.2 μm 
nitrocellulose membrane.  Precision Plus Protein Dual Xtra standard was used for band 
determination.   
Membranes were blocked (overnight, 4 °C) in 5% dry nonfat milk in 0.002% Tween 
phosphate buffered saline (PBS-T) and probed (1 h) with 6E10 monoclonal antibody 
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(1:2000), a sequence-specific antibody which binds to the N-terminal region of Aβ not 
involved in aggregation.  After washing the membrane 3 times for 5 min with PBS-T, 
HRP-conjugated anti-mouse secondary antibody (1:2000) and Precision Protein 
StrepTactin-HRP conjugate (1:2000) were allowed to bind for 45 min.  The membrane was 
again washed with PBS-T and placed in enhanced chemiluminescent reagents for 2 min.  
Images were obtained using the Gel DocTM XRS+ imaging system (Bio-Rad).  Image Lab 
software (Bio-Rad) was used to quantify the volume intensity for larger (250 kDa-100 kDa) 
and smaller oligomers (100 kDa-25 kDa) and to quantify the band intensity for monomer, 
trimer, and tetramer bands.  Intensity values for each range are reported as a fraction of the 
control.  
2.4 Assessment of Aβ1-42 Oligomer Conformation via ANS Spectroscopy 
ANS spectroscopy was used to determine if the presence of polyphenols during 
oligomerization altered the resulting oligomer conformation.  ANS, which binds to exposed 
hydrophobic molecular surfaces resulting in both a blue shift and increase in fluorescence, 
has been used extensively in protein folding to identify the presence of exposed 
hydrophobic patches and has been used to evaluate the extent of exposed hydrophobic 
residues on the surface of Aβ aggregates, including oligomers, as an indication of aggregate 
conformation.74–76  ANS was solubilized in DMSO at 50 mM and stored at 4 °C.  ANS was 
further diluted in 12 mM phosphate buffer (pH 7.4) and added to oligomers made in the 
absence (control) or presence of polyphenols for final concentrations of 1 μM Aβ1-42, 
10 μM polyphenol, and 100 μM ANS.  Fluorescence emission from 400 nm-600 nm with 
excitation at 350 nm was measured using an LS-45 luminescence spectrophotometer 
(Perkin Elmer, Waltham, MA).  Fluorescence values were determined as the integrated 
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area under the curve (IAUC) from 450-550 nm with blank (buffer or polyphenol with ANS) 
subtraction.  Results are normalized to the control.  
2.5 Assessment of Aβ1-42 Oligomer Conformation via Nile Red Spectroscopy 
For polyphenols exhibiting a self-fluorescence in the ANS wavelength range, Nile 
Red was used as an alternative probe to determine if polyphenols present during 
oligomerization alter the resulting oligomer conformation.  Nile Red is a dye which, similar 
to ANS, emits an increased fluorescent intensity with a blue shift when in the presence of 
exposed non-polar molecular surfaces.  Nile Red has also been used previously for the 
analysis of Aβ aggregate surface hydrophobicity as an indicator of conformation 
change.77,78  A 2.5 mM stock of Nile Red was prepared by dissolving Nile Red in ethanol.  
Nile Red was further diluted in phosphate buffer (pH 7.4) to 150 μM and combined with 
oligomers made in the absence (control) or presence of polyphenols for final concentrations 
of 5 μM Aβ1-42, 50 μM polyphenol, and 100 μM Nile Red.  Florescence was measured and 
results analyzed in the same fashion as described for ANS (Section 2.4) but using an 
excitation of 550 nm and emission from 580-700 nm with the IAUC being calculated from 
580-700 nm.   
2.6 Determination of Polyphenols’ Antioxidant Capacity via ORAC Assay 
Antioxidant capacities of polyphenols were assessed using the ORAC assay.  
Briefly, freshly dissolved polyphenol stock solutions (10 mM in DMSO) and Trolox, a 
vitamin E analog and strong antioxidant, standards were diluted in 75 mM potassium 
phosphate (pH 7.0) such that all samples and standards contained <5% DMSO (v/v).  
Samples and standards were mixed in a 1:6 ratio with fluorescein probe and incubated at 
37 °C for 30 min.  Free radical initiator was then added at a concentration of 80 mg/mL, 
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and fluorescence readings were obtained using a Synergy 2 multi-detection microplate 
reader (BioTek, Winooski, VT).  Fluorescence at 480 ± 20 nm excitation and 520 ± 20 nm 
emission was measured under temperature controlled conditions (37 °C) at 1 min intervals 
until the fluorescence returned to baseline (1 h).  Fluorescence was plotted versus time and 
the integrated area under the curve (IAUC) with blank (buffer) subtraction was determined.  
This net IAUC was converted to an equivalent Trolox concentration using the Trolox 
standard curve.  Results are reported as the ORAC value, which is the equivalent Trolox 
concentration per unit concentration of polyphenol.  
2.7 Media and Cell Lines   
Human neuroblastoma SH-SY5Y cells (American Type Culture Collection, 
Manassas, VA) were maintained in a 1:1 mixture of Ham’s F12K medium and DMEM.  
Medium was supplemented with 10% FBS, 100 units/mL penicillin, and 100 μg/mL 
streptomycin.  All cultures were maintained at 37°C in a humid atmosphere of 5% CO2 and 
95% air. 
2.8 Analysis of Polyphenols’ Ability to Reduce Oligomer-Induced Intracellular ROS 
via DCFH-DA Assay 
A DCFH-DA fluorescent probe was implemented to determine the effectiveness of 
polyphenols at decreasing Aβ-induced intracellular ROS.  SH-SY5Y cells were seeded at 
a density of 5 x 104 cells/well onto black-sided 96-well tissue culture plates (VWR) and 
were maintained for 24 h in F12K/DMEM, supplemented as described in Section 2.7.  Cells 
were subsequently exposed to varying treatments of Aβ1-42 oligomers and polyphenol 
diluted in 1% FBS, phenol-red free (PRF) media. Cells treated with buffer equivalent 
(phosphate buffer, <0.5% DMSO) or 25 μM H2O2 served as a vehicle and positive control, 
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respectively. Cells treated with polyphenol alone ensured there was no change to basal 
ROS levels (data not shown). After 24 h incubation (37 °C, 5% CO2), treatments were 
removed, and cells were incubated for 30 min (37 °C, 5% CO2) with DCFH-DA diluted in 
PRF, serum free media. Cellular uptake and deacetylation of DCFH-DA and subsequent 
oxidation by intracellular ROS leads to a conversion to highly fluorescent 
2’, 7’ dichlorodihydrofluorescein (DCF).  The resulting fluorescence was measured 
(Synergy 2 multi-detection microplate reader) at excitation and emission wavelengths of 
480±20 nm and 530±25 nm, respectively. Fluorescent values were converted to DCF 
concentration using a DCF standard curve. 
2.9 Analysis of Polyphenols’ Ability to Reduce Oligomer-Induced Caspase Activation   
The Image-iT LIVE Green Poly Caspases detection kit (Life Technologies, 
Carlsbad, CA), which implores a fluorescent inhibitor of caspases (FLICA) reagent for 
detection of caspase-1, -3, -4, -5, -6, -7, -8 and -9 as well as Hoechst 33342 for labeling of 
nuclei, was used to determine the ability of A1-42 oligomers to induce caspase activation 
as well as the ability of polyphenols to attenuate this response.  SH-SY5Y cells were seeded 
at a density of 1 x 106 cells/well onto 22 x 22 mm glass coverslips in 6-well tissue culture 
plates and were maintained for 24 h in F12K/DMEM, supplemented described in Section 
2.7.  Cells were subsequently exposed to varying treatments of Aβ1-42 oligomers and 
polyphenol diluted in 1% FBS media.  Cells treated with polyphenol alone ensured there 
was no change to basal caspase levels (data not shown). Cells treated with buffer equivalent 
or 1.5 U/µL TNF-α served as vehicle and positive controls, respectively.   
Following 24 h incubation (37 °C, 5% CO2), treatment was removed, and cells  
were rinsed with PRF media containing 1% FBS then incubated (37 °C, 5% CO2) for 1 h 
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with FLICA stain (diluted from 150X to 30X using PBS then to 1X using PRF media 
containing 1% FBS).  Following incubation, the stain was removed, and cells were washed 
twice with media before 10 min incubation (37 °C, 5% CO2) with Hoechst 33342 stain 
(diluted 1:1000 in PRF media containing 1% FBS).  The cells were then washed twice with 
wash buffer and mounted to slides using the kit’s fixative solution.  Labeled cells were 
imaged approximately 2 h after staining under a Nikon Eclipse 80i fluorescent microscope 
using a 40x objective.  For each slide, 5 different fields were captured for analysis.  For 
each field, both a Hoechst image and FLICA image were acquired.   
Using the Hoechst images, a custom subroutine written in Matlab (Mathworks, 
Natrick, MA) was used to quantify the total number of cells and determine the individual 
caspase activity of each cell.  The subroutine used Hoechst images to tag pixels 
representative of the boundaries of nuclei and then iteratively identified successive ‘layers’ 
of pixels moving further into the interior of the cell.  Once iterations were completed and 
convergence detected, each cell was counted.  A radius of exclusivity was defined for each 
cell within which another cell could not be identified.  Parameters used by the algorithm 
were calibrated to statistically produce the same values as manual cell counts.  The 
subroutine then utilized the nuclei boundaries (determined from the Hoechst images) to 
evaluate within FLICA images the average caspase pixel intensity within each nucleus plus 
a specified region outside the nucleus, to account for caspase staining in the cytoplasm.  
Cells displaying an average caspase pixel intensity above 5 were deemed as caspase active.  
The full Matlab code and an example output from the code can be found in Appendixes A 
and B, respectively.  For each treatment approximately 300 – 600 cells were analyzed.  
Caspase activation is reported as the fraction of caspase activated cells which is defined as 
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the total number of caspase active cells (FLICA) divided by the total number of cells 
(Hoechst). 
2.10 Statistical Analysis 
Prism 5 software (Graphpad Software, La Jolla, CA) was used for all statistical 
analysis. A one-way analysis of variance (ANOVA) was used to compare all samples to 
the respective control, and an unpaired t-test was used for comparison between samples. 
p<0.05 was considered significant. All values are expressed as the mean ± SEM.  
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CHAPTER 3
POLYPHENOLS ATTENUATE Aβ OLIGOMER-INDUCED CELLULAR RESPONSES   
3.1 Introduction  
Polyphenols have attracted attention as possible natural therapeutics for AD based 
on epidemiological studies showing correlations between polyphenol-rich diets and 
reduced incidence of AD (Section 1.3).47–49  Polyphenols contain a two aromatic carbon 
ring structure the presence of which in other compounds has shown the ability to bind to 
Aβ oligomers thereby preventing further aggregation.50,79  While studies have 
demonstrated that various polyphenols have the ability to obstruct the Aβ aggregation 
pathway,53,55,80 these studies have been primarily focused on inhibiting the formation of 
fibrils not the more damaging oligomers.  
Another potential advantage of using polyphenols for AD treatment is their 
antioxidant properties (discussed further in Section 1.4).  ROS has been implicated as a 
contributing factor in neurodegenerative diseases and the cytotoxicity of Aβ,33,81,82 making 
the reduction of ROS one therapeutic approach for AD.  Some polyphenols have 
demonstrated the ability to neutralize the increased ROS induced by Aβ aggregates.83  
Together, the observed anti-aggregation and antioxidant capabilities of polyphenols 
suggest that these natural compounds could potentially act as dual-action therapeutics for 
AD.  
This chapter investigates the polyphenols flavone (FLA), apigenin (API), luteolin 
(LUT), kaempferol (KAE), and quercetin (QUE) (Figure 3.1), which are found in an 
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assortment of foods such as herbs, apples, berries, celery and peppers.  These compounds 
have been examined for their potential health benefits in a number of areas including 
anti-ulcer84–86 anti-inflammatory84,87, anti-spasmotic85,86 and anti-cancer.84,88,89  This study 
investigates the ability of these polyphenols to attenuate the toxic effect of Aβ oligomers 
by two mechanisms 1) altering oligomer formation by changing oligomer size distribution 
and/or modulating oligomer conformation and 2) reducing Aβ oligomer–induced ROS 
through antioxidant capabilities.  The ability of polyphenols to act as dual-action 
therapeutics by acting through both mechanisms was also explored.  
The ability of polyphenols to alter oligomer size distribution was found to be 
heavily dependent on hydroxyl placement on the polyphenol, with a hydroxyl group on the 
3 position being crucial for oligomer inhibition.  Polyphenols were also found to be able to 
modulate oligomer conformation in varying ways with LUT decreasing oligomer surface 
hydrophobicity and QUE increasing oligomer surface hydrophobicity.  Altering oligomer 
conformation, rather than altering oligomer size distribution, appears to play a key role in 
reducing oligomer-induced intracellular ROS, with LUT being the only polyphenol 
capable of reducing intracellular ROS by altering oligomer formation.  All of the 
polyphenols however were able to significantly reduce oligomer-induced ROS through 
their antioxidant properties.  The antioxidant capability of LUT and QUE also resulted in 
a reduction of oligomer-induced caspase activity.  These results indicate that Aβ-mediated 
ROS second messengers play a role in caspase activation and that strong antioxidants can 
counter-act these effects.  KAE was one of the most noteworthy polyphenols, exhibiting 
dual-action reduction of both ROS and caspase activity.  Together these findings 
demonstrate the relationship between oligomer-induced ROS and caspase activity, identify 
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promising polyphenols as natural therapeutics for AD, indicate the dominant mechanism 
by which polyphenols attenuate Aβ-induced cellular responses, and identify KAE as a 
potential dual-action therapeutic for AD.  
3.2 Materials and Methods 
3.2.1 Preparation of Polyphenols 
Polyphenols FLA, KAE, and QUE were purchased from Sigma Aldrich (St. Louis, 
MO), while API and LUT were purchased from Indofine Chemical Company 
(Hillsborough Township, NJ).  All polyphenols were freshly dissolved in DMSO to a 
concentration of 10 mM to be used in experiments.  
3.2.2 Preparation of Aβ1-42 Oligomers  
 Aβ1-42 oligomers were formed in the absence (control) or 10-fold excess of either 
FLA, API, LUT, KAE or QUE, as described in Section 2.2.  
3.2.3 Determination of Aβ1-42 Oligomer Size via SDS-PAGE and Western blot 
To determine whether polyphenols present during oligomerization alter oligomer 
size distribution, SDS-PAGE with Western blotting was performed as described in Section 2.3.  
Image Lab software was used for quantification of both larger (250 kDa – 100 kDa) and 
smaller (100 kDa – 25 kDa) oligomers as well as monomer, trimer, and tetramer species.  
Intensity values for each range are reported as a fraction of the control (oligomers formed 
in absence of polyphenol).  
3.2.4 Assessment of Aβ1-42 Oligomer Conformation via ANS Spectroscopy 
 ANS spectroscopy was used as described in Section 2.4 to determine if the presence 
of polyphenols during oligomerization altered the resulting oligomer conformation.  
Fluorescence values were determined as the IAUC from 450-550 nm with blank (buffer or 
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polyphenol with ANS) subtraction.  The effect KAE has on oligomer conformation was 
unable to be tested via ANS due to the self-fluorescence associated with this polyphenol. 
Results are normalized to control oligomers. 
3.2.5 Assessment of Polyphenol Antioxidant Capacity via ORAC Assay 
Antioxidant capacities of polyphenols were assessed using the ORAC assay as 
described in Section 2.6.  Results are reported as the ORAC value, which is the equivalent 
Trolox concentration per unit concentration of polyphenol.  
3.2.6 Evaluation of Aβ1-42 Oligomer-Induced Intracellular ROS  
 An OxiSelect™ intracellular ROS assay kit was implemented to assess the ability 
of oligomers to increase intracellular ROS as well as the effectiveness of polyphenols to 
attenuate this increase.  SH-SY5Y cells were seeded and maintained as described in 
Sections 2.7 and 2.8.  To determine the effect that polyphenol-induced changes in oligomer 
size and conformation had on Aβ-induced intracellular ROS, Aβ1-42 oligomers formed in 
the presence or absence (control) of polyphenols were diluted in 1% FBS, PRF media and 
added to cells at final concentrations of 0.01 μM Aβ1-42 oligomers and 0.1 μM polyphenol.  
To assess the effectiveness of polyphenols’ antioxidant capabilities at decreasing 
Aβ-induced intracellular ROS, cells were treated simultaneously with 40 μM polyphenol 
and 0.01 μM control Aβ1-42 oligomers.  Additionally, cells were treated with 0.01 μM Aβ1-42 
oligomers formed in the presence of polyphenol plus an additional 40 μM polyphenol to 
determine the potential of polyphenols to serve as dual-action therapeutics by reducing 
Aβ-induced intracellular ROS via both mechanisms (altering oligomer formation and 
antioxidant capability).  Intracellular ROS was assessed as described in Section 2.8.  
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Resulting fluorescent values were blank subtracted and converted to DCF concentration 
using a DCF standard curve. 
3.2.7 Evaluation of Aβ1-42 Oligomer-Induced Caspase Activation   
 The Image-iT LIVE Green Poly Caspases detection kit was used as described in 
Section 2.9 to determine the ability of polyphenols to attenuate Aβ1-42 oligomer-induced 
caspase activation.  SH-SY5Y cells were seeded and maintained as described in Sections 
2.7 and 2.9 and then exposed to varying treatments of 0.01 μM Aβ1-42 oligomers and 40 μM 
polyphenol diluted in 1% FBS media as described in Section 3.2.6 for the intracellular ROS 
assay.  Caspase activation is reported as the fraction of caspase activated cells which is 
defined as the total number of caspase active cells (FLICA) divided by the total number of 
cells (Hoechst).  
3.3 Results 
3.3.1 Polyphenols alter Aβ oligomer size distribution  
To evaluate the ability of polyphenols to alter oligomerization, Aβ1-42 oligomers 
were formed in the absence (control) or presence of each polyphenol.  The size distribution 
of the resulting oligomers was assessed using SDS-PAGE and Western blot.  When 
separation was performed on a 4-20% Tris-glycine gel (Figure 3.2 A), only FLA was 
unable to reduce the formation of oligomers in both the 250-100 kDa (Figure 3.2 B) and 
100-25 kDa (Figure 3.2 C) size ranges, indicating that the presence of hydroxyl groups is 
crucial for disruption of oligomerization.  API, LUT, KAE, and QUE all significantly 
reduced the quantity of 250-100 kDa oligomers (Figure 3.2 B), with KAE exhibiting the 
most pronounced effect, a >95% reduction.  Additionally, both flavonols (KAE and QUE) 
were significantly more effective at reducing the formation of 250-100 kDa oligomers than 
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the flavones (API and LUT), demonstrating that the hydroxyl at the 3 position is important 
to the inhibition process.  Conversely, when comparing API and KAE to their 
3’ hydroxylated analogs (LUT and QUE, respectively), no significant difference in 250-
100 kDa oligomers is observed, suggesting that the hydroxyl at this position is less crucial 
for inhibition.  
API, KAE, and QUE also significantly reduced the formation of 100-25 kDa 
oligomers (Figure 3.2 C).  Again, KAE exhibited the most pronounced inhibition, reducing 
formation of these oligomers by nearly 65%.  Interestingly, addition of a hydroxyl at the 
3’ position, to convert API to LUT, results in a loss of inhibitory effect; however, addition 
of a hydroxyl at the 3 position, to convert LUT to QUE, regains this inhibitory capability.  
Furthermore, moving the hydroxyl from the 3’ position to the 3 position, to convert LUT 
to KAE, also regains this inhibitory capability.  Together, these results demonstrate the 
importance of hydroxyl placement to the inhibitory capabilities of polyphenols and support 
the importance of a hydroxyl at the 3 position.  
When separation was performed on a 16.5% Tris-tricine gel (Figure 3.2 D), none 
of the polyphenols examined significantly altered the amount of tetramer formed (Figure 
3.2 E), and only the presence of FLA and KAE resulted in a significant decrease in trimer 
formation (Figure 3.2 F).  Dimer species were not evaluated as they have been shown to 
be effected by SDS when crosslinking is not employed to stabilize the dimer structure.90  
The most pronounced polyphenol-induced change occurred in the amount of monomeric 
Aβ present (Figure 3.2 G), with all polyphenol samples except QUE exhibiting 
significantly less monomer than the control.  Together, the decrease in monomer, trimer, 
and tetramer species observed when oligomers are formed in the presence of API, LUT, 
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and KAE could indicate that the concomitant reduction of 250-25 kDa oligomers is caused 
by shifting the oligomer size distribution into higher molecular weight aggregates.  
Additionally, polyphenols may not directly bind to small Aβ species but instead interact 
primarily with Aβ oligomers. 
3.3.2 Polyphenols modulate Aβ oligomer conformation 
To determine whether the presence of polyphenols during oligomerization alters 
oligomer conformation, Aβ1-42 oligomers formed in the absence (control) or presence of 
each of the polyphenols were assessed for alterations in surface hydrophobicity using ANS.  
This florescent dye binds to exposed hydrophobic residues to give a shifted and enhanced 
fluorescence (Figure 3.3 A-D).  Oligomers formed in the presence of LUT exhibited 
significantly less surface hydrophobicity than oligomers formed alone, while oligomers 
formed in the presence of QUE exhibited significantly higher surface hydrophobicity when 
compared to the control (Figure 3.3 F).  Thus, polyphenols not only modulate oligomer 
conformation but do so in varying ways.  Oligomers were unchanged in conformation by 
FLA and API, again demonstrating the importance of polyphenol hydroxyl placement to 
polyphenol modulation of oligomerization.   
3.3.3 Aβ oligomers increase intracellular ROS and caspase activity in human 
neuroblastoma cells 
 To verify the physiological activity of Aβ1-42 oligomers, their ability to increase 
intracellular ROS and stimulate caspase activity was evaluated using SH-SY5Y 
neuroblastomas cells.  Levels of intracellular ROS were assessed using the DCFH-DA 
probe, which undergoes intracellular metabolization by ROS to fluorescent DCF.  When 
cells were treated for 24 h with 0.01 µM Aβ1-42 oligomers, a 50% increase in intracellular 
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ROS was observed over cells exposed to buffer equivalent (vehicle) (Figure 3.4 A).  In 
fact, this increase in intracellular ROS is similar to that observed for cells treated with 
25 µM H2O2, a known inducer of intracellular ROS.
91–93  Similarly, 24 h exposure of 
SH-SY5Y neuroblastoma cells to 0.01 µM Aβ1-42 oligomers stimulated caspase activity.  
While cells treated with buffer equivalent (vehicle) displayed negligible caspase activation, 
approximately 50% of the cells treated with Aβ oligomers exhibited caspase activity 
(Figures 3.4 B-C).  The level of Aβ1-42 oligomer-induced caspase activation paralleled that 
observed for cells exposed to 1.5 U/µL TNF-α, shown previously to induce caspase in 
neuronal cell models.94–96  Together, these results demonstrate the damaging physiological 
effects of oligomers at nanomolar Aβ concentrations.  
3.3.4 Polyphenols exhibit antioxidant capacity 
The antioxidant capability of polyphenols was evaluated using an ORAC assay, 
which employs a florescent probe that is subject to decay in the presence of free radicals.  
As a result, prolonged fluorescence upon incubation with a polyphenol is indicative of 
antioxidant capacity.  All polyphenols presented strong antioxidant capacity (Figure 3.5 
A), with FLA, API, LUT, and KAE exhibiting a capacity similar to that of the Trolox 
standard and QUE exhibiting a significantly higher antioxidant capacity than Trolox.  In 
addition, both API and QUE displayed significantly greater antioxidant capacity than LUT 
and KAE, demonstrating the influence of hydroxyl placement upon polyphenol antioxidant 
capacity.  
3.3.5 Polyphenols reduce Aβ oligomer-induced intracellular ROS 
As evidenced by the data above, polyphenols modulate oligomer formation and 
possess strong antioxidant capability and therefore may have the potential to attenuate Aβ 
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oligomer-induced intracellular ROS (Figure 3.4 A).  In addition, these mechanisms may 
work in concert to synergistically reduce this increase in ROS.  Each of these possibilities 
was examined using the DCFH-DA probe to assess intracellular ROS following cellular 
treatments designed to isolate these individual mechanisms of action.   
To determine if the observed alterations to oligomer size (Figure 3.2) and 
conformation (Figure 3.3) can attenuate oligomer-induced intracellular ROS, A1-42 
oligomers were prepared in the presence of 10-fold excess polyphenol and diluted to 
0.01 µM for cellular treatment.  When intracellular ROS was evaluated following 24 h 
treatment, only LUT was able to significantly reduce Aβ oligomer-induced intracellular 
ROS (Figure 3.5 B, open bars).  Additionally, simultaneous treatment (24 h) of cells with 
40 µM polyphenol and 0.01 µM Aβ1-42 oligomers formed in the absence of polyphenol was 
performed to probe whether the observed polyphenol antioxidant capacity (Figure 3.5 A) 
can attenuate oligomer-induced intracellular ROS.  Here, all compounds significantly 
lowered Aβ oligomer-induced intercellular ROS (Figure 3.5 B, closed bars).  Treatments 
including API, LUT, or QUE exhibited ~50% reduction in ROS, while KAE proved 
inferior to these compounds (p<0.05), eliciting the weakest ability to reduce intracellular 
ROS through antioxidant capabilities.  FLA was also inferior to API and LUT at reducing 
A oligomer-induced intracellular ROS through antioxidant capabilities (p<0.05 and 
p<0.01, respectively).   
To determine whether polyphenols can act through these two mechanisms in 
concert to decrease A oligomer-induced intracellular ROS, cells were treated 
simultaneously with 40 µM polyphenol and 0.01 µM Aβ1-42 oligomers formed in the 
presence of polyphenol.  All treatments conferred a significant reduction in intracellular 
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ROS relative to cells treated with oligomers alone (Figure 3.5 B, grey bars).  Among 
treatments, FLA was again inferior to its hydroxylated counterparts.  Moreover, when these 
dual-mechanism treatments included FLA, API, LUT, or QUE, the exhibited ROS 
reduction was similar to that observed for cellular treatment designed to isolate antioxidant 
capability.  Combined, these results demonstrate that polyphenols attenuate Aβ 
oligomer-induced intracellular ROS primarily via their antioxidant properties rather than 
by altering oligomer size and/or conformation.  However, the dual-mechanism treatment 
with KAE was able to decrease Aβ oligomer-induced intercellular ROS significantly more 
than when acting though antioxidant capability alone, demonstrating potential synergy 
between the two mechanisms for this polyphenol.     
3.3.6 Polyphenols reduce Aβ oligomer-induced caspase activation 
 The roles of polyphenol modulation of oligomerization (Figures 3.2 and 3.3) and 
antioxidant activity (Figure 3.5 A) toward reducing Aβ oligomer activation of caspases 
(Figure 3.4 B) were also examined.  Cells treated for 24 h with 0.01 M A1-42 oligomers 
prepared in the presence of polyphenols, to isolate the role of polyphenol-modulated 
oligomerization, showed no change in caspase activation compared to cells treated with 
oligomers prepared alone (Figure 3.6 A, left panels; Figure 3.6 B, open bars).  However, 
cells treated (24 h) simultaneously with 40 µM polyphenol and 0.01 µM Aβ1-42 oligomers 
formed in the absence of polyphenol, to isolate antioxidant activity, displayed a >50% 
decrease in caspase activity when either LUT or QUE were included in treatments 
(Figure 3.6 A, middle panels; Figure 3.6B, closed bars).  Furthermore, LUT and QUE were 
superior at decreasing Aβ oligomer activation of caspases compared to FLA (p<0.05 and 
p<0.01, respectively), API (p<0.05 and p<0.01, respectively), and KAE (p<0.05).  Thus, 
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polyphenol attenuation of Aβ oligomer-induced intracellular ROS through antioxidant 
capacity (Figure 3.5 B, closed bars) is paralleled by a reduction in oligomer-induced 
caspase activity, suggesting that Aβ-mediated ROS second messengers may play a role in 
caspase activation.   
Treatment of cells with 40 µM polyphenol and 0.01 µM Aβ1-42 oligomers formed 
in the presence of polyphenol, to facilitate both mechanisms in concert, again resulted in a 
significant decrease in caspase activity when either LUT or QUE were included in 
treatments, while treatments including FLA or API failed to attenuate A oligomer 
activation of caspases (Figure 3.6 A right panel; Figure 3.6 B, grey bars).  Similar to ROS 
reduction, these results parallel cellular treatments designed to isolate antioxidant 
capability, again indicating that attenuation of oligomer-induced cellular responses may be 
governed by polyphenol antioxidant capability.  Interestingly, KAE again showed potential 
for synergy between the two mechanisms by significantly decreasing oligomer-induced 
caspase activity when treatments facilitated both mechanisms, despite being ineffective 
when either mechanism was isolated.  In fact, within dual-mechanism treatments, KAE 
was superior to all other polyphenols (FLA, QUE p<0.05; API, LUT p<0.01). 
3.4 Discussion   
Epidemiological studies demonstrating that polyphenol-rich diets correlate with a 
reduced incidence of AD has made polyphenols promising candidates for natural AD 
therapeutics.47–49  Additionally, the ability of polyphenols to intervene in the Aβ 
aggregation pathway50,53,55,79,80 and their ability to mitigate various diseases through their 
antioxidant capabilities,62–64 gives polyphenols the potential to synergistically attenuate 
AD pathogenesis.  The present study investigated the ability of polyphenols FLA, API, 
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LUT, KAE and QUE to reduce Aβ oligomer-induced intracellular ROS and caspase 
activation by 1) altering oligomer formation and 2) acting as antioxidants.  The ability of 
these two mechanism to synergistically reduce oligomer-induced cellular responses was 
also explored.  These investigations identified that while the studied polyphenols primarily 
reduce oligomer-induced cellular responses through their antioxidant capabilities, KAE is 
able to synergistically attenuate oligomer-induced cellular responses.  
The effect Aβ oligomers have on cellular responses was investigated by evaluating 
changes to intracellular ROS and caspase activation.  Aβ1-42 oligomers at a concentration 
of 0.01 µM were found to increase intracellular ROS in SH-SY5Y cells by a 1.4 fold 
increase, a similar increase to that observed for treatment with 25 µM H2O2 (Figure 3.4 A).  
Oligomers were also shown to significantly increase caspase activity (Figure 3.4 C) which 
regulates vital cell networks responsible for inflammation and apoptosis.38  These results 
support previous findings that Aβ aggregates increase both ROS and caspase activation.97–
101  Since the upregulation of ROS has been implicated in various neurodegenerative 
diseases82 and caspase activation has been shown to further the pathology of AD by 
stimulating apoptosis, inducing tau cleavage, promoting tau tangle formulation, and 
cleaving APP,82,102 these observations suggest that attenuating oligomer-induced 
intracellular ROS and caspase activation could be a key therapeutic strategy for AD 
treatment.    
All polyphenols tested exhibited high antioxidant capacity (Figure 3.5 A), 
paralleling with previous studies investigating polyphenols as antioxidants.103–106  This 
antioxidant strength translated to an exceptional attenuation of oligomer-induced cellular 
responses, with all polyphenols significantly reducing Aβ oligomer-induced intracellular 
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ROS (Figure 3.5 B, closed bars).  Additionally, LUT and QUE were able to reduce 
oligomer-induced caspase activation through their antioxidant capabilities (Figure 3.6 B, 
closed bars).  The superiority of LUT and QUE over the other polyphenols tested is likely 
due to their 3’,4’ catechol structure, which has been suggested as a key structural element 
for cellular protection by polyphenols.107  For all polyphenols except KAE, the reduction 
of oligomer-induced cellular responses when both mechanisms of action were used was 
similar to the reduction observed when only the polyphenols’ antioxidant activity was 
employed (Figures 3.5 B and 3.6 B), indicating these polyphenols predominately reduce 
oligomer-induced cellular responses through their antioxidant capabilities instead of by 
altering oligomer formation.  This finding correlates with other studies that have suggested 
antioxidant capability is the primary mechanism by which polyphenols rescue cells from 
Aβ cytotoxicity.44,108   
Despite all hydroxylated polyphenols significantly altering oligomer formation 
(Figure 3.2 B-C and Figure 3.3), only LUT-induced changes to oligomers resulted in a 
reduction of intracellular ROS (Figure 3.5 B, open bars) and oligomer-induced caspase 
activation remained unchanged by oligomer alterations (Figure 3.6 B, open bars).  While 
LUT was inferior to the other hydroxylated polyphenols at altering oligomer size 
distribution, it was the only polyphenol capable of reducing oligomer surface 
hydrophobicity.  Increased oligomer surface hydrophobicity has been suggested as a 
primary governing factor in oligomer toxicity109–111 and computational models have 
indicated that increased surface hydrophobicity promotes the insertion of oligomers into 
the cell membrane.110  Combined, these results suggest that modulating the oligomer 
conformation by reducing surface hydrophobicity may be more effective at attenuating 
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oligomer-induced cellular responses than by altering oligomer size distribution.  
Contrastingly, previous studies have shown that polyphenol-induced changes to Aβ 
aggregates can greatly effect aggregate cellular responses.  Fibrils made in the presence of 
myricetin showed attenuation of MTT reduction in HEK 293 cells80 and multiple 
flavonoids attenuated MTT reduction in PC12 cells by altering fibril formation.104  This 
conflicting data could imply that other polyphenols have a greater potential at reducing 
oligomer-induced cellular responses or that polyphenols are more effective at reducing Aβ 
aggregate-induced responses by altering fibril formation rather than by altering oligomer 
formation.  Alternatively, the reduction in toxicity observed by these studies may be 
partially due to other neuroprotective effects, such as antioxidant capability, as the final 
cell treatment of polyphenol in these studies ranged from 1–50 µM.  These neuroprotective 
effects are much less likely to occur in the present study because of the low final treatment 
concentration of polyphenol (0.1 µM).  
KAE was the only polyphenol tested that was able to synergistically reduce 
oligomer-induced cellular responses despite having no impact when only altering oligomer 
formation and being unable to reduce caspase activation through antioxidant capabilities 
alone (Figure 3.5 B and 6 B).  While the exact mechanism was not investigated, KAE has 
been shown to protect against Aβ-induced toxicity in SH-SY5Y cells.112  Additionally, 
KAE’s antioxidant and anti-aggregation capabilities led to a reduction of Aβ-induced 
cytotoxicity in PC12 cells.104  These findings demonstrate the potential of KAE as a 
therapeutic for AD by synergistically attenuating oligomer-induced cellular responses.  
Among the observed alterations to oligomer formation, key structural elements 
were identified that allow polyphenols to alter oligomer size distribution.  FLA was the 
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only polyphenol tested unable to reduce the amount of larger oligomers formed (Figure 
3.2 A-C) and was also unable to alter oligomer conformation (Figure 3.3), indicating the 
importance of polyphenol hydroxylation for oligomer alteration.  KAE and QUE were 
found to be superior to API and LUT at altering oligomer size distribution (Figure 3.2 B), 
demonstrating the importance of a hydroxyl group at the 3 position.  However, a hydroxyl 
at the 3’ position was found to be less crucial, with LUT and QUE displaying no increase 
in oligomer inhibition compared to API and KAE.  Previous studies have concluded that a 
4’ hydroxyl group on the polyphenols fisetin and 3, 3’, 4’, 5, 5’-pentahydroxyflavone is 
key to their ability to inhibit Aβ fibril formation.113,114  All polyphenols in this study except 
FLA contained a 4’ hydroxyl group, suggesting this hydroxyl group may be a key factor to 
oligomer inhibition as well.  These same studies also cited the 3’ hydroxyl group as being 
crucial for Aβ fibril inhibition.  However, this hydroxyl group was found to not 
significantly improve oligomer inhibition, suggesting that the optimum polyphenol 
structure for altering oligomer and fibril formation may be different. 
The reduction to monomer, trimer, and tetramer Aβ species by polyphenols 
(Figure 3.2 D-G) suggests that the polyphenols are not directly interacting with these 
smaller Aβ species to prevent the formation of larger oligomers but instead are shifting the 
oligomer size distribution towards larger aggregates. Other studies have shown that various 
polyphenols can only interact or bind with Aβ aggregates once the aggregates have 
acquired a certain structure.54,83,115  These studies along with the polyphenol-induced 
changes observed for 25-250 kDa oligomers support the idea that polyphenols are more 
effective at interacting with larger Aβ oligomers than Aβ monomer, trimer and tetramer 
species.  
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Through a combination of biophysical and cellular assays, this study has 
determined the ability of five polyphenols to attenuate oligomer-induced cellular 
responses.  All polyphenols displayed excellent antioxidant capabilities, which resulted in 
a significant reduction in oligomer-induced intracellular ROS.  For LUT and QUE, their 
antioxidant capabilities were additionally able to reduce Aβ oligomer-induced caspase 
activation.  While LUT was also able to reduce oligomer-induced intracellular ROS by 
alerting oligomer formation, this compound along with FLA, API, and QUE primarily 
attenuated oligomer-induced cellular responses through their antioxidant capabilities.  
Interestingly, KAE demonstrated the ability to synergistically reduce both ROS and 
caspase activation when both mechanisms of action worked in concert despite having little 
effect when the mechanisms were used separately.  Together, these findings identify 
several promising polyphenols as natural therapeutics for AD and provide insight into their 
mechanism of action. 
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Figure 3.1 Polyphenol structures.  Structures of flavone (FLA), apigenin 
(API), luteolin (LUT), kaempferol (KAE), and quercetin (QUE), which were 
evaluated for their ability to disrupt A oligomerization and cellular activity. 
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Figure 3.2 Polyphenols alter Aβ oligomer size distribution.  Aβ oligomers 
were prepared in the absence (control, CONT) or presence of polyphenols 
flavone (FLA), apigenin (API), luteolin (LUT), kaempferol (KAE), or 
quercetin (QUE).  Briefly, Aβ monomer was combined with polyphenol in 
DMSO, and oligomerization was initiated via dilution into phosphate buffer 
containing 1 µM NaCl, for final concentrations of 15 µM Aβ, 150 µM 
polyphenol, and 2.5% DMSO.  Reactions were incubated for 30 min at 25 °C 
then stabilized via addition of Tween (0.1%).  Resulting oligomer products 
were resolved by SDS-PAGE on either a 4-20% Tris-glycine gel (panel A) or 
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a 16.5% Tris-tricine gel (panel D), transferred to nitrocellulose membrane, 
and probed with 6E10 antibody.  Images are representative of 3-5 
independent experiments.  Using volumetric analysis in conjunction with the 
4-20% Tris-glycine gel images (panel A), oligomer species within size ranges 
of 250-100 kDa (panel B) and 100-25 kDa (panel C) were quantified.  Using 
band intensity analysis in conjunction with the 16.5% Tris-tricine gel images 
(panel D), tetramer (panel E), trimer (panel F) and monomer (panel G) 
species were quantified.  Reported results are normalized to control, indicted 
by the dashed line with a value of 1 and representing no change.  Error bars 
indicate SEM, n=3-5. 
*
p<0.05, 
**
p<0.01, and 
***
p<0.001 versus control; 
†
p<0.05 and 
††† 
p<0.001 versus flavone; 
+
p<0.05, 
++
p<0.01, and 
+++
p<0.001 
between samples.  
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Figure 3.3 Polyphenols alter Aβ oligomer surface hydrophobicity.  Aβ 
oligomers were prepared in the absence (CONT, panel A) or presence of 
polyphenols flavone (FLA, panel B), apigenin (API, panel C), luteolin (LUT, 
panel D), or quercetin (QUE, panel E) as described in Figure 3.2.  Resulting 
oligomer products were diluted in ANS solution for final concentrations of 
1 µM Aβ
1-42
, 10 µM polyphenol, and 100 µM ANS.  Fluorescence emission 
was measured from 400-600 nm with excitation at 350 nm (panels A-E).  
Solid line indicates sample reading, and dashed line indicates blank reading 
(buffer or polyphenol with ANS).  F) Fluorescence values were determined 
as the IAUC from 450-550 nm, corrected by blank subtraction.  Corrected 
fluorescence was normalized to the control, indicted by the dashed line with 
a value of 1 and representing no change.  Error bars indicate SEM, n=3-4. 
*
p<0.05 versus control; 
†
p<0.05 and 
†††
p< 0.001 versus flavone; 
+
p<0.05 and 
++
p<0.01 between samples. 
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Figure 3.4 Aβ oligomers increase intracellular 
ROS and caspase activation in human 
neuroblastoma cells.  SH-SY5Y cells were 
incubated for 24 h with buffer equivalent (vehicle, 
VEH) or 0.01 µM Aβ oligomers (Aβ).  A) 
Intracellular ROS was evaluated using the DCFH-
DA probe, as described in Section 2.8.  Treatment 
with 25 µM H
2
O
2
 served as positive control.  Results 
are expressed as the fold-increase in intracellular 
ROS relative to the vehicle.  Error bars indicate 
SEM, n=14.  B) Caspase activation was evaluated via 
staining with FLICA reagent for detection of 
caspase-1, -3, -4, -5, -6, -7, -8 and -9 (green) in 
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conjunction with nuclear (Hoechst) staining (blue).  
Treatment with 1.5 U/µL TNF-α served as positive 
control.  Scale bar represents 50 μm.  Images are 
representative of 8-13 independent experiments.  C) 
Using custom MATLAB functions, cellular caspase 
activation was determined from Hoechst and FLICA 
images to quantify the total number of cells and the 
number of caspase activated cells, respectively, as 
described in Section 3.3.  Results are reported as the 
fraction of caspase activated cells.  Error bars 
indicate SEM, n=8-13. ♦♦♦p<0.001 vs. vehicle.  
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Figure 3.5 Polyphenols possess potent antioxidant capability 
and reduce Aβ oligomer-induced intracellular ROS A) 
Polyphenols flavone (FLA), apigenin (API), luteolin (LUT), 
kaempferol (KAE), and quercetin (QUE) were diluted in 75 mM 
phosphate (pH 7.0) and subjected to an ORAC assay alongside a 
Trolox standard as described in Section 2.6.  ORAC values are 
expressed as the equivalent Trolox concentration per molar 
concentration of polyphenol.  ORAC value of Trolox is indicated 
by the dashed line.  Error bars indicate SEM, n=3-4. **p<0.01 
versus Trolox; +p<0.05 between samples.  B) SH-SY5Y cells 
were incubated for 24 h with or without 40 µM polyphenol and 
 41 
with 0.01 µM Aβ oligomers formed in either the presence or 
absence of polyphenols as indicated.    Treatments were designed 
to isolate mechanisms for polyphenol attenuation of ROS: 
modulation of oligomer formation (open bars), antioxidant action 
(closed bars), or both mechanisms in concert (grey bars).  
Intracellular ROS was evaluated using the DCFH-DA probe, as 
described in Section 3.2.6.  Results are expressed as the percent 
decrease in intracellular ROS relative to treatment with Aβ 
oligomers alone.  Error bars indicate SEM, n=3-4. *p<0.05, 
**p<0.01, and ***p<0.01 vs. Aβ oligomers alone.   
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Figure 3.6 Polyphenols reduce Aβ-induced caspase activation.  
A) SH-SY5Y cells were treated for 24 h with indicated treatments 
of Aβ oligomers and 40 µM flavone (FLA), apigenin (API), luteolin 
(LUT), kaempferol (KAE), or quercetin (QUE) as described in 
Figure 3.5. Caspase activation was evaluated via staining with 
FLICA reagent for detection of caspase-1, -3, -4, -5, -6, -7, -8 and -9.  
Scale bar represents 50 μm.  Images are representative of 3-4 
independent experiments.  Additional images for remaining 
polyphenols and coinciding Hoechst images can be found in 
Appendix C.  B) Cellular caspase activation was determined from 
Hoechst and FLICA images as described in Figure 3.4 to isolate 
mechanisms for polyphenol attenuation of caspase activation: 
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modulation of oligomer formation (A left column, B open bars), 
antioxidant action (A middle column, B closed bars), or both 
mechanisms (A right column, B grey bars).   Results are reported as 
the fraction of caspase activated cells.  Error bars indicate SEM, 
n=3-5.  **p<0.01 and ***p<0.001 versus Aβ oligomers alone.  
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CHAPTER 4
QUERCETIN METABOLITES ARE EQUALLY AS EFFECTIVE AS QUERCETIN AT 
ATTENUATING Aβ OLIGOMER-INDUCED CELLULAR RESPONSES  
4.1 Introduction  
Antioxidants have long been known to exert numerous health benefits and have 
been studied as possible therapeutics for a host of diseases.33,116–119  As mentioned in 
Section 1.3, some of the most studied antioxidants are polyphenols due to epidemiological 
studies supporting the health benefits from high polyphenol intake.47,48,120–123  QUE, one 
of the polyphenols studied in Chapter 3, is the main polyphenol in the human diet124,125 and 
has demonstrated promise as a natural therapeutic for a variety of ailments including 
cardiovascular disease, cancer, neurodegenerative disease, and diabetes.33,121,123,126  
However, since QUE is readily metabolized in the liver and intestines leaving very little 
free QUE, scientist now believe many of the health benefits attributed to oral 
administration of QUE could actually be attributed to its metabolites.126–129  In fact, studies 
have shown that QUE metabolites have greater accumulation than QUE due to slower 
elimination from the body128,130 and that these metabolites exhibit similar or greater 
protective effects.126,131  Due to the evidence supporting the therapeutic properties of both 
QUE and its metabolites, this study sought to compare the therapeutic potential of QUE 
and three of its most common metabolites, rhamnetin (RHA), isorhamnetin, (IRHA), and 
tamarixetin (TAM), in relation to AD (Figure 4.1).  
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 Polyphenols, including QUE, have been of interest as natural therapeutics for AD 
due to their ability to reduce ROS via their antioxidant capabilities.  Oxidative stress caused 
by the overproduction of ROS is believed to play a key role in the pathology of 
AD.33,47,82,132  The primary cause of the increase in ROS is the aggregation of the amyloid-
β (Aβ) protein associated with AD pathology.  Aβ aggregates have been proven to produce 
both H2O2 and free radicals; furthermore, a positive feedback loop has been suggested with 
Aβ aggregate-induced oxidative stress leading to the production of more Aβ 
aggregates.33,133,134  Studies have shown the ability of polyphenols and specifically QUE to 
attenuate the increased ROS created by Aβ aggregates.33,68,69  While the results of QUE are 
promising, there has been little investigation into the ability of QUE metabolites to reduce 
Aβ aggregate-induced ROS.   
 The antioxidant strength that polyphenols possess are not the only attribute that 
make them promising therapeutics for AD.  As mentioned in Section 1.3, polyphenols have 
also demonstrated the ability to intervene in the Aβ aggregation pathway resulting in fewer 
aggregates being formed, aggregates of altered size and conformation, and, most notably, 
aggregates with reduced cytotoxicity.54,68–70,113,114  While QUE has been studied for its 
ability to inhibit the formation of Aβ fibrils,68–70 data is lacking on the ability of QUE and 
its metabolites to alter the formation of Aβ oligomers, the most toxic Aβ aggregate 
species,23–25,135 and if these alterations can attenuate oligomer-induced cellular responses.  
This chapter investigated the ability of QUE, RHA, IRHA, and TAM to attenuate 
Aβ oligomer-induced cellular responses though two separate mechanisms: their 
antioxidant capability and their ability to alter oligomer formation.  Additionally, the 
potential of these polyphenols to serve as dual-action therapeutics by acting through both 
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mechanisms was determined.  Due to the antioxidant nature of polyphenols and the key 
role ROS is believed to play in AD pathology, the ability of polyphenols to reduce Aβ 
oligomer-induced intracellular ROS was investigated.  Additionally, the ability of 
polyphenols to reduce Aβ oligomer-induced caspase activation was determined since 
intracellular ROS is known to trigger caspase activation136–139 and since caspase activation 
has demonstrated the ability to further AD pathology by inducing apoptosis, cleaving APP, 
inducing tau cleavage, and promoting tau tangle formation.82,102  
Investigations revealed that not only can QUE reduce Aβ oligomer-induced cellular 
responses but that its metabolites are just as effective at doing so.  Results further showed 
that polyphenols attenuate Aβ oligomer-induced cellular responses through different 
mechanisms, with QUE and TAM primarily acting via their antioxidant properties while 
IRHA is more effective when altering oligomer formation.  Notably, RHA is equally 
effective at reducing oligomer-induced cellular responses regardless of which mechanism 
is employed.  These results support the idea that QUE is not solely responsible for the 
attenuation of AD pathology but, that many of the therapeutic effects attributed to it are a 
result of QUE metabolites. 
4.2 Materials and Methods   
4.2.1 Preparation of Polyphenols 
 Polyphenols QUE, RHA, and IRHA were purchased from Sigma Aldrich 
(St. Louis, MO) and TAM was purchased from Fisher Scientific (Waltham, MA).  All 
polyphenols were freshly dissolved in DMSO to a concentration of 10mM to be used in 
experiments.  
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4.2.2 Assessment of Polyphenol Antioxidant Capacity via ORAC Assay 
Antioxidant capacities of polyphenols were assessed using the ORAC assay as 
described in Section 2.6.  Results are reported as the ORAC value, which is the equivalent 
Trolox concentration per unit concentration of polyphenol.  
4.2.3 Preparation of Aβ1-42 Oligomers  
 Aβ1-42 oligomers were formed in the absence (control) or presence of a 10-fold 
excess of either QUE, RHA, IRHA, or TAM as described in Section 2.2.  
4.2.4 Determination of Aβ1-42 Oligomer Size via SDS-PAGE and Western blot 
To determine whether polyphenols present during oligomerization alter oligomer 
size distribution, SDS-PAGE with Western blotting was performed as described in Section 2.3.  
Image Lab software was used for quantification of both larger (250 kDa – 100 kDa) and 
smaller (100 kDa – 25 kDa) oligomers as well as monomer, trimer, and tetramer species.  
Intensity values for each range are reported as a fraction of the control.  
4.2.5 Assessment of Aβ1-42 Oligomer Conformation via ANS and Nile Red Spectroscopy 
Nile Red was used as described in Section 2.5 to determine if polyphenols could 
alter oligomer conformation when present during oligomerization.  Nile Red emits an 
increased fluorescent intensity with a blue shift when in the presence of exposed non-polar 
molecular surfaces.  A LS-45 luminescence spectrophotometer (Perkin Elmer, Waltham, 
MA) was used to measure the fluorescence (excitation = 550 nm, emission = 580 – 700 
nm) and the IAUC was calculated with blank (Nile Red plus buffer or polyphenol) 
subtraction.   
Upon examination of blank readings, it was discovered that QUE interferes with 
the fluorescent signal of Nile Red, therefore ANS was used as an alternative for this 
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compound.  ANS experiments were performed as described in Section 2.4 and fluorescence 
values were determined as the IAUC from 450-550 nm with blank subtraction.  Results for 
both Nile Red and ANS are reported as a fraction of the control.  
4.2.6 Cell Culture and Treatment 
SH-SY5Y cells were maintained as described in Section 2.7.  To determine the 
ability of strong antioxidants to attenuate Aβ1-42 oligomer-induced cellular responses, cells 
were simultaneously treated with 0.01 µM Aβ1-42 oligomers and 10 µM polyphenol diluted 
in media.  This lower concentration of polyphenol was used rather than the 40 µM used in 
Chapter 3 due to some of QUE’s metabolites causing increased cellular responses at the 
higher concentration.  To explore the potential of polyphenols to reduce Aβ1-42 oligomer-
induced cellular responses by altering oligomer formation, rather than through their 
antioxidant properties, cell were treated with Aβ1-42 oligomers formed in the presence or 
absence (control) of polyphenols and diluted in media to final concentrations of 0.01 μM 
Aβ1-42 oligomers and 0.1 μM polyphenol.  Additionally, cells were treated with 0.01 μM 
Aβ1-42 oligomers formed in the presence of polyphenol plus 10 μM polyphenol to determine 
the potential of polyphenols to serve as dual-action therapeutics by reducing Aβ1-42 
oligomer-induced cellular responses via both mechanisms (antioxidant capability and 
altering oligomer formation). 
4.2.7 Evaluation of Antioxidants Ability to Reduce Aβ1-42 Oligomer-Induced Intracellular 
ROS  
An OxiSelect™ intracellular ROS assay kit was implemented as described in 
Section 2.8 to assess the ability of polyphenols to reduce oligomer-induced intracellular 
ROS.  Cells were exposed to varying treatments of Aβ1-42 oligomers and polyphenol diluted 
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in phenol red free media containing 1% FBS as described in Section 4.2.6.  Resulting 
fluorescent values were blank subtracted and converted to DCF concentration using a DCF 
standard curve.  Results are reported as the intracellular ROS as fraction of negative 
control. 
4.2.8 Evaluation of Aβ1-42 Oligomer-Induced Caspase Activation   
 The Image-iT LIVE Green Poly Caspases detection kit was used as described in 
Section 2.9 to determine the ability of polyphenols to attenuate Aβ1-42 oligomer-induced 
caspase activation.  Cells were exposed to varying treatments of Aβ1-42 oligomers and 
polyphenol diluted in media containing 1% FBS media as described in Section 4.2.6.  
Results are expressed as the fraction (FLICA/Hoechst) of caspase activated cells. 
4.3 Results 
4.3.1 Antioxidant capability of polyphenols result in reduced Aβ oligomer-induced cellular 
responses  
An ORAC assay was used to assess the antioxidant strength of the compounds.  All 
compounds exhibited similar antioxidant capability to that of the Trolox standard 
(Figure 4.2 A).  While replacing the hydroxyl group with a methoxy group on the fused 
ring (transitioning from QUE to RHA) did not affect antioxidant strength, replacing 
hydroxyl groups on the attached ring to form IRHA and TAM did result in a loss in 
antioxidant strength, indicating that hydroxyls on the attached ring are more crucial for 
antioxidant capability.  
The ability of polyphenols to reduce Aβ oligomer-induced cellular responses via 
antioxidant capability was assessed in SH-SY5Y human neuroblastoma cells using a 
DCFH-DA probe and an Image-iT LIVE Green Poly Caspases detection kit to monitor 
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intracellular ROS and caspase activation, respectively.  Cells treated with buffer or 10 µM 
polyphenol alone demonstrated that the concentrations of buffer and polyphenol used did 
not alter basal ROS and caspase levels (data not shown).  As demonstrated in Section 3.3.3, 
Aβ oligomers stimulate an increase in intracellular ROS in SH-SY5Y cells compared to 
cell treatment of buffer alone (Figure 4.2 B, p<0.001).  In fact, the response in intracellular 
ROS was slightly greater for 0.01 µM Aβ oligomers than for the positive control (25 µM 
H2O2).  Simultaneous cell treatment with 0.01 µM Aβ oligomers and 10 µM of either QUE, 
RHA, or IRHA showed a significant decrease in intracellular ROS compared to cells 
treated with Aβ oligomers alone (Figure 4.2 B).  TAM, however, failed to significantly 
impact the oligomers’ effect on ROS.  Paralleling with their antioxidant strength, QUE and 
RHA had the greatest effect on decreasing Aβ oligomer-induced ROS, with both 
compounds reducing intracellular ROS significantly more than IRHA and TAM.  
 As demonstrated in Section 3.3.3, Aβ oligomers also increase caspase activation in 
SH-SY5Y cells compared to buffer alone (Figure 4.2 C-E, p<0.001).  This increase is 
similar to that observed for cells treated with the positive control (1.5 U/µL TNF-α), 
demonstrating the potency of Aβ oligomers on cellular responses.  Analogous with their 
ability to reduce intracellular ROS, QUE and RHA were able to significantly reduce 
oligomer-induced caspase activation (Figure 2 C and E) thus demonstrating the ability of 
strong antioxidants to attenuate multiple Aβ-induced cellular responses.  Interestingly, 
TAM, the weakest antioxidant, significantly reduced oligomer-induced caspase activation 
even though it had no effect on intracellular ROS, indicating that it may be acting through 
alternative mechanisms.   
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4.3.2 Both QUE and metabolites alter Aβ oligomer size distribution and increase oligomer 
surface hydrophobicity   
Aβ oligomers were formed in the absence (control) or presence of 10-fold excess 
of each polyphenol to evaluate alterations in oligomer size distribution and conformation.  
Resulting oligomers were evaluated using SDS-PAGE and Western blot for size 
distribution analysis (Figure 4.3 A-B).  The quantity of oligomers formed in size ranges 
250-100 kDa and 100-25 kDa was assessed (Figure 4.3 C-D) as well as the quantity of 
tetramer, trimer, and monomer species (Figure 4.3 E).  QUE proved to be the most effect 
inhibitor of oligomers 250-100 kDa in size however, RHA and TAM also significantly 
reduced the quantity of oligomers in this size range (Figure 4.3 C).  Meanwhile, IRHA 
failed to elicit any changes to the quantity of 250-100 kDa oligomers formed.  All 
polyphenols significantly reduced the amount of 100-25 kDa oligomers formed, although 
IRHA was still inferior to all other polyphenols tested (Figure 4.3 D).  The weak effect of 
IRHA in both size ranges indicates the presence of a hydroxyl group rather than a methoxy 
group on the 3’ position is crucial for inhibition.  Contrastingly, a methoxy substitution on 
both the 4’ and 7 positions (TAM and RHA) still resulted in efficient reduction of 
oligomers within both size ranges, suggesting hydroxyl groups at these positions are less 
crucial for oligomer reduction.   
The polyphenols had less of an impact on smaller Aβ species.  QUE and TAM did 
not significantly impact the quantity of monomer, trimer, or tetramer species while RHA 
and IRHA only reduced the amount of monomeric species (Figure 4.3 E).  The lack of an 
increase in monomeric Aβ when polyphenols are present indicates that the polyphenols are 
not directly binding to Aβ monomer to stop aggregates from forming but instead interact 
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primarily with Aβ oligomers.  This interaction in turn effects the ability of Aβ oligomers 
to bind to one another and/or Aβ monomer, resulting in alterations in oligomer formation.  
Oligomer conformational changes induced by the presence of the polyphenols were 
determined using either ANS or Nile Red.  Both of these fluorescent dyes bind to 
hydrophobic residues on the surface of the oligomers resulting in an increased 
fluorescence.  Due to QUE interference with Nile Red fluorescence, ANS was used to 
evaluate conformational changes caused by QUE.  All polyphenols resulted in a significant 
increase in oligomer surface hydrophobicity compared to control oligomers (Figure 4.3 F).  
TAM resulted in the largest alteration, increasing oligomer surface hydrophobicity 
significantly more than QUE, RHA, and IRHA.  
4.3.3 Polyphenol-induced alterations to Aβ oligomer formation result in reduced cellular 
responses 
 The ability of compounds to reduce Aβ oligomer-induced cellular responses by 
modifying oligomer formation was assessed using a DCFH-DA probe and an Image-iT 
LIVE Green Poly Caspases detection kit.  Oligomers were formed in the presence of each 
compound and diluted to 0.01 µM Aβ and 0.1 µM polyphenol in 1% FBS media.  
SH-SY5Y cells were treated with resulting oligomers for 24 h and compared against cells 
treated with control oligomers.  Results demonstrate that only IRHA was able to 
significantly reduce Aβ-induced intracellular ROS by altering oligomer formation 
(Figure 4.4 A).  However, both RHA and IRHA were able to significantly reduce Aβ 
oligomer-induced caspase activation, while QUE and TAM had no effect (Figure 4.4 B-C).  
These results prove that polyphenols can attenuate Aβ oligomer-induced cellular responses 
not just through antioxidant capability but also by altering oligomer formation.  
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4.3.4 Polyphenols attenuate Aβ oligomer-induced cellular responses via different 
mechanisms but do not possess dual-action potential 
 To determine if polyphenols possessed a dual-action ability to decrease Aβ 
oligomer-induced cellular responses via two separate mechanisms (antioxidant capability 
and altering oligomer formation), cells were treated with 0.01 µM Aβ oligomers formed in 
the presence of polyphenol and an additional 10 µM polyphenol.  The ability of all 
polyphenols to decrease Aβ oligomer-induced intracellular ROS was similar to the 
reduction observed when only antioxidant capability was utilized, with only QUE and RHA 
causing a significant reduction in intracellular ROS (Figure 4.5 A).  This demonstrates that 
this set of polyphenols primarily attenuate oligomer-induced intracellular ROS via their 
antioxidant capability with minimal attenuation of ROS resulting from altering oligomer 
formation or dual-action attenuation.  
 All polyphenols were able to significantly decrease Aβ oligomer-induced caspase 
activation when both mechanisms were utilized (Figure 4.5 B-C).  Interestingly, the 
primary mechanism to achieve this decrease varies for each polyphenol.  QUE and TAM 
only attenuate caspase activation when their antioxidant mechanism is employed, whereas 
IRHA acts solely through its ability to alter oligomer formation.  RHA is the only 
compound that results in a significant reduction in caspase activation through the use of 
either mechanism.  No increase in efficacy was observed for any polyphenol when both 
mechanisms were exerted compared to when only the polyphenol’s dominate mechanism 
was used (either mechanism for RHA).  This demonstrates that while all polyphenols can 
reduce Aβ oligomer-induced caspase activation, these polyphenols do not possess 
dual-action potential.  
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4.4 Discussion   
Natural antioxidants, including polyphenols, have been of interest as possible 
therapeutics for a variety of ailments.33,116–119  QUE is a widely studied polyphenol that has 
demonstrated potential for a host of therapeutic applications.33,121,123,126  However, studies 
have suggested that it is not simply QUE but also its metabolites created upon oral 
administration that are the source of these health benefits.126,128,130,131  This study 
investigated the ability of QUE and three of its most common metabolites (RHA, IRHA, 
and TAM) to attenuate Aβ oligomer-induced cellular responses associated with AD.  
Investigations revealed these polyphenols can reduce Aβ oligomer-induced intracellular 
ROS and caspase activation through two separate mechanisms: their antioxidant capability 
and by altering oligomer formation.  Furthermore, studies showed that the primary 
mechanism by which the polyphenols attenuate Aβ oligomer-induced cellular responses 
varies for each polyphenol.   
 All polyphenols studied were found to be strong antioxidants with antioxidant 
capability being similar or higher than the vitamin E analog, Trolox (Figure 4.2 A).  
Additionally, QUE and RHA were shown to significantly reduce oligomer-induced 
intracellular ROS via their antioxidant capability (Figure 4.2 B).  These findings agree with 
previous studies that have shown QUE and RHA can protect against H2O2-induced 
oxidative damage140–142 and that QUE can reduce Aβ aggregate-induced ROS.143  The 
inability of IRHA and TAM to reduce oligomer-induced intracellular ROS is likely due to 
these compounds not possessing the 3’,4’-catechol structure on the attached ring that QUE 
and RHA possess.  This catechol structure increases antioxidant capability, enhances 
inhibition of lipid peroxidation, and is a common structural element in the most potent ROS 
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and RNS scavengers.103,144–146  On the other hand, IRHA has previously been shown to 
reduce H2O2-induced
147 and menadione-induced148 ROS using cell pretreatment with 
higher doses of IRHA (25 -100 µM) for shorter exposure times (45 min – 4 h).  However, 
for the purpose of investigating AD, a prolonged co-treatment with Aβ oligomers and low 
dose polyphenol is more therapeutically relevant.  
 Polyphenols QUE, RHA, and TAM were all effective inhibitors of Aβ oligomer-
induced caspase activation (Figure 4.2 C).  This parallels with the ability of QUE and RHA 
to reduce intracellular ROS which is known to trigger caspase activation.136–139  However, 
since TAM was unable to attenuate oligomer-induced intracellular ROS, its ability to 
reduce caspase activation suggests that the antioxidant capacity of polyphenols can act 
through multiple mechanisms to attenuate oligomer-induced cellular responses.  
Antioxidants have been shown to reduce caspase activation by inhibiting the release of 
cytochrome c149 and various polyphenols, including QUE, are believed to inhibit AP-1 
activation and the JNK pathway, both of which stimulate caspase activation.150  TAM is 
likely acting via one such mechanism to attenuate Aβ oligomer-induced caspase activation 
rather than by reducing ROS.  Both QUE and TAM have been shown to decrease neuronal 
cell loss caused by oxidative damage151 and to inhibit cholinesterases,152 the reduction of 
which has been one therapeutic strategy for AD.  Combined these studies support the 
findings that QUE, RHA, and TAM can attenuate Aβ oligomer-induced cellular responses.  
 The polyphenols investigated were found to modify Aβ oligomer formation by 
altering both the oligomer size distribution and conformation (Figure 4.3).  QUE, RHA, 
and TAM all significantly reduced the amount of oligomers formed in both the 250-100 
kDa and 100-25 kDa size ranges (Figure 4.3 C-D).  IRHA had the weakest effect on 
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oligomers in both size ranges, completely failing to reduce oligomers 250-100 kDa in size.  
These results indicate that a methoxy group substitution on QUE at the 3’ position (IRHA) 
drastically effects oligomer inhibitory capabilities, while a substitution at the 4’ or 7 
position (TAM and RHA) has little effect.  Investigation of other polyphenol structures has 
likewise shown that the 3’ hydroxyl is important for Aβ aggregate inhibition, while a 
hydroxyl at the 7 position is not.113,114  While the 4’ hydroxyl group has also been identified 
as key for aggregate inhibition,113,114 the inhibitory capability of TAM suggests that mere 
functionalization of the 4’ position is satisfactory for effective aggregate inhibition.  
Although data is lacking on the effect these polyphenols have on oligomer aggregation, 
studies have shown that QUE and RHA, but not IRHA, inhibit Aβ fibril formation70,114,153 
further supporting the current findings.  The polyphenols had little effect on smaller Aβ 
species (Figure 4.3 E) with only RHA and IRHA having any impact and only at reducing 
the amount of Aβ monomer.  Other studies have shown that various polyphenols can only 
interact or bind with Aβ aggregates and not Aβ monomer.54,83,115  These results paired with 
the current findings that polyphenols can alter oligomer formation and previous studies 
demonstrating polyphenols alter fibril formation,70,113,114,153 suggest that these polyphenols 
are more effective at interacting with Aβ aggregates than Aβ monomer.  
 All of the polyphenols significantly altered Aβ oligomer conformation by 
increasing surface hydrophobicity (Figure 4.3 F).  Some polyphenols have the ability to 
alter Aβ fibril conformation by effecting the β-sheet structure.112,154,155  This study shows 
the ability of polyphenols to act earlier on in the aggregation process by altering oligomer 
conformation.  Substitution of a hydroxyl group with a methoxy group on QUE at either 
the 3’ or 7 position (IRHA and RHA) had no effect on the resulting oligomer conformation 
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however, a substitution at the 4’ position (TAM) further increased the surface 
hydrophobicity of the oligomers.  While alterations to oligomer size distribution were 
determined by the 3’ position of the polyphenol, alterations to oligomer conformation were 
dependent on the functionalization of the 4’ position, highlighting the ability to modify 
different oligomer characteristics by altering polyphenol structure.   
 When testing the ability of polyphenols to attenuate oligomer-induced cellular 
responses by modifying oligomer formation, it was found that only IRHA had the ability 
to significantly reduce Aβ oligomer-induced intracellular ROS (Figure 4.4 A).  
Interestingly this parallels with IRHA having the weakest effect on oligomer size 
distribution while still significantly altering oligomer conformation.  A change in oligomer 
conformation has been shown to have drastic effects on toxicity even among oligomers of 
similar size,109,156,157 indicating that changing the conformation, without shifting the size 
distribution, may be an effective approach to attenuate oligomer-induced responses.  On 
the other hand, typically an increase in surface hydrophobicity has led to more toxic Aβ 
aggregates,109,156,157 suggesting the reduction in intracellular ROS observed may also 
involve another mechanism.   
 When present during oligomerization, RHA and IRHA were able to drastically 
reduce the amount of Aβ oligomer-induced caspase activation (Figure 4.4 B-C).  Since 
QUE produced similar alterations to oligomer size as RHA and since QUE, RHA, and 
IRHA all created oligomers with similar surface hydrophobicity, QUE not having a similar 
effect on caspase activation suggests that RHA and IRHA are acting via an additional 
mechanism.  One such mechanism could be the inhibition of oligomer-cell interactions.  It 
is believed that one contributing factor of AD pathology is the ability of Aβ aggregates, 
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including oligomers, to interact with, bind to, and disrupt the cell membrane thereby 
triggering proinflammatory and proapoptotic pathways.158–162  The interaction of methoxy 
groups with Aβ oligomers, rather than just the hydroxyl groups present in QUE, may be 
altering the oligomers so that they are unable to interact with cell receptors.  This has been 
observed with Aβ aggregates formed in the presence of various inhibitors and has been 
proposed as a possible therapeutic strategy.163–165  This would also further explain the 
ability of IRHA to reduce Aβ oligomer-induced intracellular ROS when present during 
oligomer formation.    
 When each polyphenol was allowed to both exert antioxidant capabilities and alter 
oligomer formation, QUE and RHA successfully reduced oligomer-induced intracellular 
ROS (Figure 4.5 A).  This reduction was similar to QUE and RHA’s effect when only 
exerting their antioxidant capability, demonstrating that these polyphenols primarily 
reduce oligomer-intracellular ROS via antioxidant strength and do not possess dual-action 
potential.  All polyphenols were able to attenuate Aβ oligomer-induced caspase activation 
when acting via both mechanisms (Figure 4.5 B-C).  While they did not exert dual-action 
potential, this study did reveal the primary mechanism by which each polyphenol reduces 
oligomer-induced caspase activation.  QUE and TAM both primarily reduce caspase 
activation via their antioxidant properties while the reduction observed by IRHA stems 
from IRHA-induced alterations to oligomer formation.  Interestingly, RHA is equally 
effective at reducing oligomer-induced caspase activation regardless of which mechanism 
is employed.   
 This study determined the ability of QUE and three of its metabolites (RHA, IRHA, 
and TAM) to exert antioxidant capability, alter Aβ oligomer size distribution, and alter 
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oligomer conformation.  In vitro studies revealed that these polyphenols can reduce Aβ 
oligomer-induced intracellular ROS and caspase activation.  However, the difference seen 
among the polyphenols in attenuating these cellular responses showed that they act through 
different mechanisms.  This study demonstrates that QUE is likely not solely responsible 
for the attenuation of AD pathology observed in epidemiological studies but that many of 
the therapeutic effects attributed to QUE are a result of the formation of QUE metabolites 
which also attenuate oligomer-induced cellular responses.    
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Figure 4.1 Structure of quercetin metabolites. Quercetin (QUE) and 
its metabolites rhamnetin (RHA), isorhamnetin (IRHA), and tamarixetin 
(TAM).   
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Figure 4.2 Quercetin and metabolites possess strong antioxidant capability 
and reduce Aβ oligomer-induced cellular responses.  A) Antioxidant 
capabilities of quercetin (QUE) and metabolites rhamnetin (RHA), isorhamnetin 
(IRHA), and tamarixetin (TAM) were assessed using the ORAC assay as 
described in Section 2.6.  Antioxidant capacity is shown as ORAC value which 
is the equivalent Trolox concentration per molar concentration of polyphenol.  
ORAC value of Trolox = 1, indicated by the dashed line.  Error bars indicate 
SEM, n=4.  SH-SY5Y cells were treated with 0.01 µM Aβ oligomers alone (Aβ) 
or simultaneously treated with 0.01 µM Aβ oligomers and 10 µM polyphenol.  
After 24 h incubation, intracellular ROS and caspase activity was quantified.  B) 
A DCFH-DA probe was used for intracellular ROS quantification. Buffer alone 
(-) and 25 µM H2O2 (+) served as negative and positive controls, respectively.  
Results are expressed as the intracellular ROS as fraction of negative control. 
Error bars indicate SEM, C-E) For assessment of caspase activation an Image-iT 
LIVE Green Poly Caspases detection kit and a Nikon Eclipse 80i fluorescent 
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microscope was used to acquire nuclear Hoechst (E, left column) and FLICA 
labeled active caspase (E, right column) images.  Buffer alone (-) and 1.5 U/µL 
TNF-α (+) served as negative and positive controls, respectively (D).  Scale bars 
represent 50 μm.  Images are representative of 3 independent experiments.  
Caspase activation was determined using custom MATLAB functions to 
quantify Hoechst and FLICA images.  Results are reported as the fraction 
(FLICA/Hoechst) of caspase activated cells (C). B-C) Error bars indicate SEM, 
n=3 for samples, n=12 for controls and Aβ alone. *p<0.05, **p<0.01, and 
***p<0.001 vs Aβ alone, ††p<0.01 vs QUE and +p<0.05 between samples.   
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Figure 4.3 Quercetin and metabolites alter Aβ oligomer size 
distribution and conformation   Aβ oligomers were prepared as described 
in Section 2.2.  Oligomers were prepared in the absence (control, CONT) 
or presence of 10-fold excess quercetin (QUE), rhamnetin (RHA), 
isorhamnetin (IRHA), or tamarixetin (TAM).  Final oligomer reactions 
containing 15 µM Aβ, 150 µM polyphenol, 1 µM NaCl, and 2.5% DMSO 
were incubated for 30 min (25°C).  To determine the amount of oligomers 
formed, oligomer products were resolved by SDS-PAGE on either A) a 
4-20% tris-glycine gel or B) a 16.5% tris-tricine gel, transferred to 
nitrocellulose membrane, and probed with 6E10 antibody.  Images are 
representative of 3-5 independent experiments.  Volumetric analysis was 
used to quantify oligomer species within size ranges of C) 250-100 kDa and 
D) 100-25 kDa.  E) Band intensity analysis was used to quantify monomer 
(open bars), trimer (closed bars) and tetramer (grey bars) species.  F) To 
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assess alterations in oligomer conformation, oligomer products were 
combined with either ANS or Nile Red and the fluorescence emissions were 
measured as described in Section 2.4 and 2.5.  Fluorescence values were 
determined as the IAUC, corrected by blank subtraction.  All results are 
normalized to the control with a value of 1, indicted by the dashed line, 
representing no change.  Error bars indicate SEM, n=3-5.  
*
p<0.05, 
**
p<0.01, and 
***
p<0.001 vs CONT; 
†
p<0.05, 
††
p<0.01, and 
†††
p<0.001 vs 
QUE; 
+
p<0.05, 
++
p<0.01, and 
+++
p<0.001 between samples.  
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Figure 4.4 Alterations to Aβ oligomer size distribution and conformation 
reduce Aβ oligomer-induced cellular responses.  SH-SY5Y cells were 
treated with 0.01 µM Aβ oligomers formed in the absence (Aβ) or presence of 
10-fold excess of polyphenol and incubated for 24 h.  A) Intracellular ROS was 
quantified as described in Figure 4.2.  B) FLICA labeled active caspase images 
were acquired as described in Figure 4.2. Coinciding Hoechst images can be 
found in Appendix D.  Scale bar represents 50μm.  Images are representative 
of 3-4 independent experiments.  C) Hoechst and FLICA images were 
quantified using custom MATLAB functions to determine caspase activation.  
Results are reported as the fraction (FLICA/Hoechst) of caspase activated 
cells.  A and C) Error bars indicate SEM, n=3-4 for samples, n=12 for Aβ alone.  
*
p<0.05, and 
***
p<0.001 vs Aβ alone; 
†
p<0.05 vs QUE; 
+
p<0.05 between 
samples.   
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Figure 4.5 Dual-action potential of quercetin and metabolites to reduce Aβ 
oligomer-induced cellular responses.  SH-SY5Y cells were treated with 
0.01 µM Aβ oligomers formed in the absence (Aβ) or presence of 10-fold 
excess polyphenols.  Cells treated with oligomers formed in the presence of 
polyphenols were treated simultaneously with an additional 10 µM polyphenol 
as described in Section 4.2.6.  Cells were incubated for 24 h.  A) Intracellular 
ROS was quantified as described in Figure 4.2.  B) FLICA labeled active 
caspase images were acquired as described in Figure 4.2. Coinciding Hoechst 
images can be found in Appendix D.  Scale bar represents 50μm.  Images are 
representative of 3-4 independent experiments.  C) Hoechst and FLICA images 
were quantified using custom MATLAB functions to determine caspase 
activation.  Results are reported as the fraction (FLICA/Hoechst) of caspase 
activated cells.  A and C) Error bars indicate SEM, n=3-4 for samples, n=12 
for Aβ alone.  
*
p<0.05, 
**
p<0.01, and 
***
p<0.001 vs Aβ alone.   
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CHAPTER 5 
CONCLUSIONS 
As the number of people with AD continues to rise, so does the desperate need for 
a therapeutic.  Attenuating AD pathology by either targeting Aβ oligomer formation 
directly or reducing the cellular responses created by oligomers has been one proposed 
therapeutic strategy.  Polyphenols have been suggested as potential natural therapeutics for 
AD based on epidemiological studies correlating polyphenol-rich diets with a reduced 
incidence of AD.47–49,120–123  Based on these and other supporting data, this study sought to 
identify polyphenols that can reduce Aβ oligomer-induced cellular responses by 1) altering 
oligomer formation and 2) exerting antioxidant capabilities.  The ability of polyphenols to 
function as dual-action therapeutics for AD by acting through both mechanisms was also 
explored.   
In Chapter 3, several polyphenols were identified that alter oligomer formation by 
changing the oligomer size distribution.  The set of polyphenols examined varied by 
number and placement of hydroxyl groups, thereby allowing the identification of key 
structural elements that are crucial for oligomer inhibition.  FLA, the only compound with 
no hydroxyl groups, was unable to alter oligomer size distribution demonstrating the 
importance of hydroxylation.  While the number of hydroxyl groups did not directly 
correlate with the potential of polyphenols to intervene in oligomer formation, the 
placement of the hydroxyl groups on the polyphenols did.  Addition of a hydroxyl group 
to the 3 position significantly increased the ability of polyphenols to alter oligomer size 
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distribution, whereas the presence of a hydroxyl group at the 3’ position had a slightly 
negative impact.  In Chapter 4, the effect of substituting a hydroxyl group with a methoxy 
group was investigated to determine whether hydroxyl groups specifically or just 
functionalization in general was necessary for effective oligomer inhibition.  Results 
showed that a substitution at the 4’ or 7 position had little effect but, that substitution at the 
3’ position drastically reduced inhibitory capabilities.  In Chapter 3, adding a hydroxyl 
group to the 3’ position of KAE (to form QUE) slightly decreased efficacy; however, in 
Chapter 4 when a methoxy group is added to the same position (to form IRHA) there is 
nearly a complete loss in all inhibitory capability.  This result demonstrates the effect the 
type of functionalization has on the ability of polyphenols to alter oligomer formation.  
Together, these findings provide insight into the optimum polyphenol structure to target 
oligomer formation.  
The ability of polyphenols to alter oligomer conformation was also investigated.  In 
Chapter 3, FLA was unable to alter oligomer conformation, again demonstrating the need 
for polyphenol functionalization.  Contrastingly, functionalized polyphenols not only 
demonstrated the ability to alter oligomer conformation but the ability to do so in opposing 
ways.  LUT significantly reduced oligomer surface hydrophobicity.  Conversely, adding a 
hydroxyl to LUT at the 3 position (to form QUE) yielded the inverse effect: creating 
oligomers with significantly higher surface hydrophobicity.  In Chapter 4, substituting a 
hydroxyl group with a methoxy group at the 3’ or 7 position of QUE did not affect oligomer 
surface hydrophobicity while substitution at the 4 position significantly increased surface 
hydrophobicity.  These results further demonstrate the importance of the location and type 
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of functionalization on polyphenols to altering oligomer formation and provide further 
insight into the optimal polyphenol structure to target oligomerization.  
The effect polyphenol-induced changes to oligomer formation had on cellular 
responses was examined by evaluating changes in intracellular ROS and caspase 
activation.  Alterations to oligomer formation by LUT and IRHA were shown to reduce 
oligomer-induced intracellular ROS in SH-SY5Y cells.  These polyphenols were some of 
the least effective at shifting oligomer size distribution but still significantly altered 
oligomer conformation.  Therefore, altering oligomer conformation rather than oligomer 
size distribution could be a key property required for effective AD therapeutics.  
Additionally, RHA and IRHA attenuated oligomer-induced caspase activation, suggesting 
that oligomer alterations by polyphenols containing methoxy groups may limit oligomer-
cell interactions.  Combined, these studies demonstrate that polyphenols have potential as 
natural therapeutics for AD by altering oligomer formation. 
All polyphenols tested exhibited high antioxidant strength; however, a reduction in 
antioxidant capability was observed for IRHA and TAM which have a disrupted 3’, 
4’-catechol structure due to a methoxy group substitution.  Antioxidant capability was 
shown to translate into a reduction in Aβ oligomer-induced intracellular ROS with only 
TAM unable to significantly reduce ROS.  Several polyphenols were also able to reduce 
Aβ oligomer-induced caspase activation via their antioxidant properties.  These studies 
demonstrate that polyphenols have potential as natural therapeutics for AD by reducing 
oligomer-induced cellular responses via their antioxidant properties.  
While the polyphenols in Chapter 3 were observed to predominantly attenuate Aβ 
oligomer-induced cellular responses through their antioxidant capabilities, some 
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polyphenols investigated in Chapter 4 were shown to also act through different 
mechanisms.  While QUE and TAM both primarily reduced oligomer-induced cellular 
responses via their antioxidant properties, IRHA instead attenuated cellular responses by 
altering oligomer formation.  Interestingly, RHA was equally effective at reducing 
oligomer-induced caspase activation regardless of which mechanism was employed.  
Unfortunately, simultaneous use of both mechanisms did not significantly improve RHA’s 
impact on cellular responses.  KAE, however, did show potential as a dual-action 
therapeutic with significantly greater reduction of both ROS and caspase when both 
mechanisms of attenuation were used compared to when either mechanism used alone.   
In summary, this study has successfully characterized the ability of several 
polyphenols to attenuate oligomer-induced cellular responses and identified via which 
mechanism they accomplish this attenuation.  This information will direct future work in 
identifying the most promising polyphenols for use as natural therapeutics for AD.   
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CHAPTER 6 
FUTURE PERSPECTIVES
While only one of the tested polyphenols exhibited dual-action ability, polyphenols 
were shown to act through different mechanisms to attenuate oligomer-induced cellular 
responses.  Therefore, the potential exists for two polyphenols, acting through different 
mechanisms, to synergistically attenuate cellular responses.  To test this theory, cells would 
be treated simultaneously with oligomers made in the presence of a polyphenol shown to 
be effective at reducing cellular responses by altering oligomer formation (RHA or IRHA) 
and with a polyphenol shown to be effective via their antioxidant capability (LUT, QUE,  
or TAM).  Testing different combinations of the polyphenols indicated above would 
identify potential therapeutic cocktails that could attenuate AD pathology using two 
separate mechanisms.  
The use of cell culture assays allowed two separate mechanisms by which 
polyphenols can attenuate oligomer-induced cellular responses to be explored.  However, 
these observed effects may not translate into effective oral therapeutics considering the 
extent to which many polyphenols are metabolized in vivo and the need for the polyphenols 
to cross the blood-brain barrier.  Therefore, animal models are needed to further 
characterize the potential of promising polyphenols as natural therapeutics for AD.  Several 
mouse models of AD have been designed, such as the Tg-SwDi mouse model that develops 
neuronal and vascular amyloid pathology as well as brain-associated inflammation.166,167  
Daily administration of polyphenols to these mice for several months prior to the onset of 
 72 
Aβ deposition and memory deficits would determine the impact of long-term exposure to 
polyphenols on AD pathology.  The effects of polyphenol administration could be assessed 
by using behavior testing, such as the Morris water maze test and contextual fear 
conditioning, and by evaluating AD pathology markers such as Aβ burden and cerebral 
inflammation.168  Combined, these additional studies would further determine which 
polyphenols are best suited for use as natural therapeutics for AD and thus direct future 
drug development. 
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APPENDIX A: MATLAB CODE
The following code was designed by Nick van der Munnik and was calibrated 
against manual cell counts.  
This script calls the "ghostcells2.m" function which determines cell viability 
based on an absolute threshold of Caspase pixel intensity (referred to as FITC within the 
code) averaged within a circle centered around the point of convergence of an identified 
nuclei.  
DAPI=[]; 
FITC=[]; 
Fig=[]; 
dataoutput=zeros(numsam,3); 
index=zeros(numsam,1); 
tic; 
 
i=1; 
while i<=9 && i<=numsam 
    DAPI=uint8(imread(strcat('DAPI00',num2str(i),'.jpg'))); 
    FITC=uint8(imread(strcat('FITC00',num2str(i),'.jpg'))); 
    [dataoutput(i,:),Fig]=ghostcells2(DAPI,FITC); 
    index(i,1)=i; 
    imwrite(Fig,strcat('MLImage',num2str(i),'.tif')); 
    figure 
    imshow(Fig) 
    i=i+1; 
end 
 
while i>9 && i<=numsam 
    DAPI=uint8(imread(strcat('DAPI0',num2str(i),'.jpg'))); 
    FITC=uint8(imread(strcat('FITC0',num2str(i),'.jpg'))); 
    [dataoutput(i,:),Fig]=ghostcells2(DAPI,FITC); 
    index(i,1)=i; 
    imwrite(Fig,strcat('MLImage',num2str(i),'.tif')); 
    figure 
    imshow(Fig) 
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    i=i+1; 
end 
fprintf('average time per sample (minutes)') 
toc/(60*numsam) 
fprintf('    Index   Cells Active_Cells  Caspase/Hoeschst) 
dataoutput=[index dataoutput] 
 
Below is the subroutine ghostcells2.  
 
function [data,output]=ghostcells2(D,F) 
p=D(:,:,3);         % Uses blue channel for Hoechst 
fit=F(:,:,2);       % Uses green channel for Caspase 
dim=size(p); 
rdim=dim(1,1); 
cdim=dim(1,2); 
 
dthresh=5;          % Caspase activation threshold 
crad=50;            % Radius of cell 
 
mincon=38; 
minex=40; 
maxcon=130; 
nsteps=5; 
pstore=p; 
cells=0; 
deadcells=0; 
q=p*0; 
s=p*0; 
outputf=p*0; 
outputd=p*0; 
ltag=p*0; 
dtag=p*0; 
rtag=p*0; 
output=zeros(rdim*2,cdim); 
bin=p*0; 
negative=p*0; 
cidrinit=zeros(1000,1); 
cidcinit=zeros(1000,1); 
 
%Count Cells 
for step=0:nsteps 
    thresh=110-step*(100/nsteps); 
    p=pstore; 
    %Make Black/White 
    for i = 1:rdim 
        for j = 1:cdim 
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            if p(i,j) >= thresh 
                p(i,j) = 100;                 
            else 
                p(i,j) = 0; 
            end 
            if step==nsteps 
                if p(i,j) >= thresh 
                    bin(i,j) = 1; 
                    negative(i,j)=0; 
                else 
                    bin(i,j) = 0; 
                    negative(i,j)=100; 
                end 
            end 
        end     
    end 
    %Outline Cells 
    for i = 2:rdim-1 
        for j = 2:cdim-1 
            if p(i,j) ==100 
                if p(i-1,j)==0 && p(i+1,j)==100 
                    p(i,j)=200; 
                elseif p(i-1,j)==100 && p(i+1,j)==0 
                    p(i,j)=200; 
                elseif p(i,j-1)==0 && p(i,j+1)==100 
                    p(i,j)=200; 
                elseif p(i,j-1)==100 && p(i,j+1)==0 
                    p(i,j)=200; 
                end 
            end 
        end     
    end 
    p(1,:)=200; 
    p(:,1)=200; 
    p(rdim,:)=200; 
    p(:,cdim)=200; 
    %Squeeze cell outlines by half minimum feature size 
    for k=0:(mincon/2) 
        for i = 2:rdim-1 
            for j = 2:cdim-1 
                if p(i,j)==100 
                    if p(i-1,j)==200+k && p(i+1,j)==100 
                        p(i,j)=200+k+1; 
                    elseif p(i-1,j)==100 && p(i+1,j)==200+k 
                        p(i,j)=200+k+1; 
                    elseif p(i,j-1)==200+k && p(i,j+1)==100 
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                        p(i,j)=200+k+1; 
                    elseif p(i,j-1)==100 && p(i,j+1)==200+k 
                        p(i,j)=200+k+1; 
                    elseif p(i-1,j)>=200 && p(i+1,j)>=200 
                        p(i,j)=200+k+1; 
                    elseif p(i,j-1)>=200 && p(i,j+1)>=200 
                        p(i,j)=200+k+1; 
                    end 
                end 
            end     
        end 
    end 
    for i = 1:rdim 
        for j = 1:cdim 
            if p(i,j) >= 200 
                p(i,j) = 200; 
            end 
        end     
    end 
    for i = 2:rdim-1 
        for j = 2:cdim-1 
            if p(i,j) ==100 
                if p(i-1,j)==200 && p(i+1,j)==200 
                    p(i,j)=200; 
                elseif p(i,j-1)==200 && p(i,j+1)==200 
                    p(i,j)=200; 
                end 
            end 
        end     
    end 
    p=p-q;    
    for k=0:(maxcon-mincon)/2 
        %Test for convergence, exclude area around confirmed cell 
        for i = (mincon/2):rdim-(mincon/2) 
            for j = (mincon/2):cdim-(mincon/2) 
                if p(i,j) ==100 
                    index=0; 
                    if p(i-2,j)>=200 && p(i+2,j)>=200 
                        if p(i,j-2)>=200 && p(i,j+2)>=200 
                            index=1; 
                        end 
                    end 
                    if p(i-2,j-1)>=200 && p(i+2,j-1)>=200 
                        if p(i+1,j-2)>=200 && p(i+1,j+2)>=200 
                            index=index+1; 
                        end 
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                    end 
                    if p(i-1,j-2)>=200 && p(i-1,j+2)>=200 
                        if p(i-2,j+1)>=200 && p(i+2,j+1)>=200 
                            index=index+1; 
                        end 
                    end 
                    if index==3 
                        if p(i-2,j-2)>=200 && p(i+2,j-2)>=200 
                            if p(i-2,j+2)>=200 && p(i+2,j+2)>=200 
                                cells = cells+1; 
                                for m = -minex:minex;                     
                                    for n = -minex:minex; 
                                        if sqrt(m^2+n^2)<=minex 
                                            if i-m>=1 && i-m<=rdim 
                                                if j-n>=1 && j-n<=cdim 
                                                    q(i-m,j-n)=1000; 
                                                    p(i-m,j-n)=-1000; 
                                                end 
                                            end 
                                        end 
                                    end 
                                end 
                                cidrinit(cells)=i; 
                                cidcinit(cells)=j; 
                                s(i,j)=1000; 
                                for m = 0:9; 
                                    for n = 0:9; 
                                        ltag(i-4+m,j-4+n)=1000; 
                                    end 
                                end 
                            end 
                        end 
                    end 
                end 
            end     
        end 
        %Continue to Squeeze 
        for i = 2:rdim-1 
            for j = 2:cdim-1 
                if p(i,j)==100 
                    if p(i-1,j)==200+k && p(i+1,j)==100 
                        p(i,j)=200+k+1; 
                    elseif p(i-1,j)==100 && p(i+1,j)==200+k 
                        p(i,j)=200+k+1; 
                    elseif p(i,j-1)==200+k && p(i,j+1)==100 
                        p(i,j)=200+k+1; 
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                    elseif p(i,j-1)==100 && p(i,j+1)==200+k 
                        p(i,j)=200+k+1; 
                    elseif p(i-1,j)==200+(k+1) && p(i+1,j)==200+k 
                        p(i,j)=200+k+1; 
                    elseif p(i-1,j)==200+k && p(i+1,j)==200+(k+1) 
                        p(i,j)=200+k+1; 
                    elseif p(i,j-1)==200+(k+1) && p(i,j+1)==200+k 
                        p(i,j)=200+k+1; 
                    elseif p(i,j-1)==200+k && p(i,j+1)==200+(k+1) 
                        p(i,j)=200+k+1; 
                    end 
                end 
            end     
        end 
    end 
end 
 
%Segment Cell Clusters 
pc=imcomplement(pstore); 
pmin=imimposemin(pc,~bin|s); 
p=watershed(pmin); 
p=uint8(p); 
for i = 1:rdim 
    for j = 1:cdim 
        if p(i,j) >0 
            p(i,j) = 100;                 
        else 
            p(i,j) = 0; 
        end 
    end     
end 
outputf=(p/100).*fit; 
outputd=(p/100).*pstore; 
 
%Count Caspase Active 
cvec=zeros(cells,1); 
cidr=cvec; 
cidc=cvec; 
for i=1:cells 
    cidr(i,1)=cidrinit(i,1); 
    cidc(i,1)=cidcinit(i,1); 
end 
 
for c=1:cells 
    i=cidr(c,1); 
    j=cidc(c,1); 
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    fitcsum=uint32(0); 
    cmoves=0; 
    for m=-crad:crad 
        for n=-crad:crad 
            if i+m>1 && i+m<rdim && j+n>1 && j+n<cdim 
                if sqrt(m^2+n^2)<=crad 
                    cmoves=cmoves+1; 
                    fitcsum=fitcsum+uint32(fit(i+m,j+n)); 
                    if sqrt(m^2+n^2)>crad-1 
                        rtag(i+m,j+n)=112; 
                    end 
                end 
            end 
        end 
    end 
    if double(fitcsum/cmoves)>=dthresh 
        deadcells=deadcells+1; 
        for m = -2:2; 
            for n = -2:2; 
                dtag(i+m,j+n)=1000; 
            end 
        end 
    end 
end 
 
outputf=outputf+ltag+rtag-dtag; 
outputd=outputd+ltag-dtag; 
output=[outputf outputd]; 
data=zeros(1,3); 
data(1,1)=cells; 
data(1,2)=caspasecells; 
data(1,3)= caspasecells/cells; 
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APPENDIX B: EXAMPLE OUTPUT FROM MATLAB CODE
 
 
 
Figure B.1 Example output from Matlab code. A) Hoechst image. B) Caspase image. 
C) Greyscale caspase image. White boxes indicate center of identified nuclei and open 
circles indicate boundary of cell within which the average pixel intensity from the 
caspase image was calculated. D) Greyscale of Hoechst image. Nuclei containing both 
a white and black box were found to have an average caspase pixel intensity above the 
set threshold and therefore counted as caspase activated cells. 
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APPENDIX C: COINCIDING IMAGES FOR FIGURE 3.6 
 
 
 
Figure C.1 Caspase images for cells treated with Aβ oligomers made in the presence 
of polyphenol. Hoechst (top panel) and caspase (bottom panel) images that coincide with 
Figure 3.6 B (open bars).  
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Figure C.2 Caspase images for cells treated with Aβ oligomers made in the absence 
of polyphenol and 40 µM polyphenol. Hoechst (top panel) and caspase (bottom panel) 
images that coincide with Figure 3.6 B (closed bars).  
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Figure C.3 Caspase images for dual-action treatment. Hoechst (top panel) and caspase 
(bottom panel) images that coincide with Figure 3.6 B (grey bars).
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APPENDIX D: COINCIDING IMAGES FOR FIGURES 4.4 AND 4.5 
 
 
 
Figure D.1 Coinciding Hoechst images for Figures 4.4 and 4.5. Hoechst images for A) 
cells treated with Aβ oligomers formed in the presence of polyphenol to coincide with 
Figure 4.5 and B) dual-action treatment to coincide with Figure 4.6. 
